Document XQYnxdgxD091wgkVLNExBwqK

DownloadViewSend us a messageRandom document
AR226-3160 DuPont-2921 TRADE SECRET Study Title H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats Laboratory Project ID: DuPont-2921 Author: Carol Finlay, B.A. Study Completed on: August 29, 2000 Performing Laboratory: E.I. du Pont de Nemours and Company Haskell Laboratory for Toxicology and Industrial Medicine Elkton Road, P.O. Box 50 Newark, Delaware 19714-0050 Work Request Number: Service Code Number: Page 1 of 91 Company Sanitized. Does not contain TSC A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 CERTIFICATION We, the undersigned, declare that this report provides an accurate evaluation of data obtained from this study. Reviewed by: Gary W. Jepson, Ph.D. Senior Research Scientist Z ? ZOi Date Reviewed by: (Qujdcti- 0. Judith C Stadler, Ph.D.. D.A.B.T. Director Dale Issued by Study Director: C-AAtoL t o Uu, Carol Finlfty, B.A. Staff Scientist -2 Company Sanitized. Does not contain T S C A CBS H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 TABLE OF CONTENTS Page C ERTIFICA TIO N .............................................................................................................................-2 LIST OF TA BLES...............................................................................................................................4 LIST OF FIG U R E S............................................................................................................................ 4 LIST OF A PPEN D IC ES..................................................................................... 4 STUDY IN FO R M A TIO N ........................................................................................... 5 STUDY PERSONNEL........................................................................................................................ 7 SUM M ARY.......................................................................................................................................... 8 INTRODUCTION............. .................................................................................................................. 9 MATERIALS AND M ETH O D S...................................................................................................... 9 A. Test Substance and Positive Control........................................................................................9 B. Test Species...............................................................................................................................9 C. Animal Husbandry...................................................................................................... 10 1. Housing Environment.... ;.......................................................................................................................... 10 2. Feed and Water........................................................................................................................................... 10 3. Identification.............................................................................................................................................. 10 4. Animal Health Monitoring Program.............................................................................. ;......................... 10 D. Quarantine and Pretest........................................... 11 E. Study Design............................................................................................................................11 F. Assignment to Groups and Study Start..................................................................................11 G. Dosing Material Preparation and Administration................................................................. 11 1. Test Substance............................................................................................................................................ 11 2. Positive Controls........................................................................................................................................ 12 3. Negative Controls..................................................:................................................................................... 12 H. Body Weights...........................................................................................................................12 I. Mortality and Clinical Observations................................................. 12 J. Collection and Analysis of Blood and Livers....................................................................... 12 K. Treatment of Fluorine Data........................................:...........................................................13 RESULTS AND DISCU SSIO N .......................................................................................................14 A. In-Life Toxicology.................................................................................................................. 14 B. Fluorine D a ta .............................................. :.......................................................................... 14 1. Factors Influencing Interpretation of Analysis..........................................................................................14 2. Positive Controls........................................................................................................................................ 14 3. Test Substance........................................................................................................... 15 CONCLUSIONS................................................................................................................................ 15 RECORDS AND SAM PLE STO R A G E............................................... 16 T A B L E S ............................................................................................................................................... 17 -3Oompany Sanitized. Does not contain TSCA r H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 FIGU RES...........................................................................................................................................23 APPENDICES.................................................................................................................................. 28 LIST OF TABLES Page 1. MEAN BODY WEIGHTS..................................................................................................................................... 18 2. MEAN BODY WEIGHT GAINS ....................................................................................................................20 3. MEAN BLOOD FLUORINE LEVELS...................................................................................................................21 4. MEAN BLOOD FLUORINE CONCENTRATION NORMALIZED TO DOSE.................................... ............ 22 LIST OF FIGURES 1. MEAN BODY WEIGHTS...................................................................................................................................... 24 2. MICROMOLAR EQUIVALENTS IN RAT BLOOD........................................................................................... 25 3.. MICROMOLAR EQUIVALENTS IN TEST COMPOUND AND POSITIVE CONTROLS............................ 27 LIST OF APPENDICES Page A. INDIVIDUAL BODY WEIGHTS.................................... :.................................................................................... 29 B. INDIVIDUAL CLINICAL OBSERVATIONS...................................................................................................... 70 C. INDIVIDUAL FLUORINE LEVELS.................................................................................................................... 83 -4 Com pany Sanitized. Does not contain T S C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats STUDY INFORMATION TEST SUBSTANCE: Haskell Number: 23925 Composition:! Known Impurities: None POSITIVE CONTROL: DuPont-2921 Haskell Number: 24019 Known Impurities: Unknown -5 Som pany Sanitized. Does not eontain T S C C i H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats STUDY INFORM ATION (Continued) POSITIVE CONTROL: DuPont-2921 Composition Known Impurities: Unknown Sponsor: E. I. du Pont de Nemours and Company Wilmington, Delaware 19898 U.S.A. Study Initiated/Completed: April 30, 1999 / (see report cover page) In-Life Initiated/Completed: May 16, 1999 / August 17, 1999 -6i&ompany Sanitized. Does not contain TS C A CB! H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats STUDY PERSONNEL Study Director: Carol Finlay, B.A. Management: Judith C. Stadler, Ph.D., D.A.B.T. Primary Technician: Richard P. Mathena Blood Fluorine Data Analysis: Gary W. Jepson, Ph.D. Management: Matthew S. Bogdanffy, Ph.D., D.A.B.T. Toxicology Report Preparation: Wanda F. Dinbokowitz Laboratory Veterinarian: Wanda L. West, D.V.M., A.C.L.A.M. + DuPont-2921 tt -7 Com pany Sanitized. Does not contain T S C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 SUMMARY The objective of this study was to evaluate the potential for H-23925, when administered by gavage, to be absorbed and to accumulate in a mammalian system. Six groups of 5 male Crl:CD(SD)IGS BR rats each were given 200 mg/kg/day of H-23925. The test substance was administered to one group of 5 rats for 5 consecutive days and to 5 groups for 10 days. Approximately 2 hours after the first dose, blood was collected from the orbital sinus of each rat from the 5-dose group. On selected days (5,10,13, 24, 52, 94) 5 rats per group were euthanized and the blood and livers were collected. Body weights and clinical signs were recorded on each day of dosing and then weekly, every other week, or every 3 weeks during the recovery period. Additionally, 3 negative controls, deionized water, com oil, and com oil/acetone (80:20), and 2 positive controls, H-24019 (10 mg/kg/day) and H-24020 (20 mg/kg/day), were tested as described for H-23925. No deaths occurred during the study. One rat dosed with the test substance, H-23925, exhibited diarrhea on test day 4. This clinical sign is considered not to be due to administration of the test substance because it was only observed on one day in a single rat. Rats dosed with H-24019 exhibited diarrhea, salivation, alopecia, black ocular discharge, and staining of various parts of the body during the dosing period. Rats dosed with H-24020 exhibited wet perineum and diarrhea during the dosing period. Alopecia was observed during the recovery period in rats dosed with H-24019, H-24020, and deionized water. The com oil and com oil/acetone negative control rats exhibited no clinical signs during the study. Comparison of body weights was complicated by the fact that there was a difference in age on test day 1 between the rats dosed with the test substance and those dosed with the positive or negative controls. Accounting for the age difference at study start and the expected rate of body weight gain, it appears that the mean body weights and mean body weight gains of the rats dosed with the test substance, H-23925, are comparable to the negative controls and equal to or greater than the positive controls. A steady-state for fluorine levels in whole blood was not achieved during 10 consecutive days of dosing with 200 mg/kg H-23925. An area under the curve (estimated to infinity) was calculated and normalized for fluorine content for the test substance and each positive control. The AUCINF/D for the fluorine component of the test substance, H-23925, was 14,886.1, compared to AUCINF/D values of 566,479.1 and 70,789.6 for the positive controls, H-24019 and H-24020, respectively. Under the conditions of this study, administration of H-23925 to male rats for 10 consecutive days resulted in low absorption and retention of fluorine in the blood. Dose adjusted areas under the curve (AUCINF/D) for positive controls, H-24019 and H-24020, were approximately 38x and 5x the AUCINF/D for the test substance. -8 Cofflpany Sanitized. Does not contain T S C A C3? H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 INTRODUCTION The objective of this study was to define the potential of H-23925 to be absorbed and to bioaccumulate in a mammalian system, as indicated by analytical determination of total fluorine in blood and liver. The test substance was compared to 2 positive controls that were materials previously shown to bioaccumulate in mammals. The daily dosage for the test substance, 200 mg/kg, was selected based on available toxicity data and the results of rangefinding studies. In the initial rangefinding study, a group of 5 male rats was dosed by oral gavage with H-23925 at a dosage of 2000 mg/kg for 5 consecutive days. A group of 5 male rats was dosed with deionized water and served as controls. The rats dosed with H-23925 experienced an overall mean body weight loss of 29 grams. In the next rangefinding study, 2 groups of 5 male rats were dosed by oral gavage with H-23925 at a dosage of 500 or 1000 mg/kg for 5 consecutive days. A group of 5 male rats was dosed with deionized water and served as controls. Overall mean body weight losses of 7 and 25 grams occurred in the rats dosed with the test substance. A group of 5 male rats was then dosed by oral gavage at a dosage of 125 mg/kg for 5 consecutive days. A group of 5 male rats was dosed with deionized water and served as controls. The rats dosed at 125 mg/kg experienced an overall mean body weight gain of 13 grams. The control group had an overall mean body weight gain of 14 grams. The dosage of 200 mg/kg was chosen for the main study and was expected to produce less than a 10% difference in mean body weight when compared to controls. All blood samples were analyzed for total fluorine content. This report contains the results of those analyses. Results from analyses of selected liver samples will be presented in a supplemental report. MATERIALS AND METHODS A. Test Substance and Positive Control The test substance, H-23925, was supplied by the sponsor as an amber liquid with some flock sediment. The positive controls, H-24019 and H-24020, were supplied by the sponsor as white solids. The test substance and positive controls appeared to be stable under the conditions of the study. No evidence of instability, such as a change in color or physical state, was observed. B. Test Species > Male Crl:CD(SD)IGS BR rats were received from Charles River Laboratories, Inc., Raleigh, North Carolina. The Crl:CD(SD)IGS BR rat was selected on the basis of extensive experience with this strain and its suitability with respect to longevity, hardiness, sensitivity, and low incidence of spontaneous diseases. -9 Com pany Sanitized. Does not contain T S C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 C. Animal Husbandry 1. Housing Environment Rats were housed singly in stainless steel, wire-mesh cages suspended above cage boards. Animal rooms were maintained on an approximate 12-hour light/dark cycle (fluorescent light) and at a temperature of 23 1C and a relative humidity of 50 10%. Occasional excursions outside the accepted ranges were minor and did not affect the study. 2. Feed and Water Tap water was provided ad libitum. All rats were fed PMI Nutrition International, Inc. Certified Rodent LabDiet 5002 chow. The feed is guaranteed by the manufacturer to meet specified nutritional requirements and to be free of specified contaminants. 3. Identification Prior to assignment to groups, each rat was temporarily identified by cage identification. After assignment to groups, an individual identification number was marked or tattooed on the tail of each rat. The information on the cage labels included the unique 6-digit Haskell animal number assigned to each rat. 4. Animal Health Monitoring Program As specified in the Haskell Laboratory animal health and environmental monitoring program, the following procedures are performed periodically to assure that contaminant levels are below those that would be expected to impact the scientific integrity of the study: Water samples are analyzed for total bacterial counts, and the presence of coliforms, lead, and other contaminants. Feed samples are analyzed for total bacterial, spore and fungal counts. Samples from freshly washed cages and cage racks are analyzed to ensure adequate sanitation by the cagewashers. Certified animal feed is used, guaranteed by the manufacturer to meet specified nutritional requirements and not to exceed stated maximum concentrations of key contaminants, including specified heavy metals, aflatoxin, chlorinated hydrocarbons, and organophosphates. The presence of these contaminants below the maximum concentration stated by the manufacturer would not be expected to impact the integrity of the study. The animal health and environmental monitoring program is administered by the attending laboratory animal veterinarian. -10- Oompany Sanitized. Does not contain T S C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 D. Quarantine and Pretest Upon arrival at Haskell Laboratory, the rats were removed from shipping cartons and quarantined for 6 days. The rats were weighed 3 times during the pretest period and examined daily for any clinically apparent signs of disease or injury. The rats were observed daily for mortality and signs of illness, injury, or abnormal behavior. On the bases of acceptable body weight gains and freedom from clinically apparent signs of disease or injury, the rats were released from quarantine by the laboratory animal veterinarian designee. E. Study Design Substance Negative Controls Deionized water Com oil Com oil:acetone Positive Controls H-24019 H-24020 Test Substance H-23925 Vehicle Dosage (mg/kg) Number of Animals Not applicable 0 0 0 30 30 30 Com oil: acetone Com oil 10 20 30 30 Deionized water 200 30 F. Assignment to Groups and Study Start After the quarantine period, the rats were selected on the bases of adequate body weight gain, freedom from any clinical signs of disease or injury, and a body weight within 20% of the mean. The selected rats were divided by computerized, stratified randomization into 6 groups of 5 rats, so that there were no statistically significant differences among group body weight means. After assignment to groups, each rat was housed individually. The last 3 digits of the animal number was marked or tattooed on the tail of each rat. The rats were between 7 and 9 weeks of age at the time of dosing. Dosing began on test day 1. Rats that were not assigned to the study were released for other laboratory purposes, or were sacrificed by carbon dioxide asphyxiation and discarded without pathological evaluation. G. Dosing Material Preparation and Administration 1. Test Substance H-23925 was mixed with deionized water so an accurate volume could be delivered. The amount of test substance each rat received was based on the body weight collected on each day of dosing and the dosing mixture concentration. The rats were dosed at a volume of 10 mL/kg of -11 - H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 body weight. The test substance was stined on a magnetic stir plate throughout the dosing procedure to maintain homogeneity. 2. Positive Controls The solid positive control compounds were suspended as emulsions in their respective vehicles. Com oil was used as the vehicle for H-24019. It was necessary to dissolve H-24020 in acetone before suspending it in com oil. The ratio of acetone to com oil was 20:80. The amount each rat received was based on the body weight collected on each day of dosing and the suspension concentration. The dose volumes did not exceed 1 mL/100 g of body weight. The dosing suspensions were stirred on a magnetic stir plate throughout the dosing procedure to maintain homogeneity. 3. Negative Controls Deionized water was chosen as a negative control because it was the vehicle for the test substance. Com oil and com oil:acetone (80:20) were chosen as negative controls because they were the vehicles for the positive controls. Each negative control rat received 1 mL of com oil or com oil:acetone. These rats were dosed in a separate room from the rats dosed with the test substance or positive controls. H. Body Weights All rats were weighed on each day of dosing. The positive and negative control rats were weighed weekly or every other week during the recovery period. The rats dosed with H-23925 were weighed weekly, every other week, or every 3 weeks during the recovery period. I. Mortality and Clinical Observations Cage-site examinations to detect moribund or dead rats and abnormal behavior and appearance among rats were conducted at least once daily throughout the study. At every weighing, each rat was individually handled and examined for abnormal behavior and appearance. J. Collection and Analysis of Blood and Livers Approximately 2 hours after the first dose, 1-2 mL of blood was collected into EDTA tubes from the orbital sinus of each rat from Group I. At all other selected time points, 5 rats/group were euthanized by carbon dioxide anesthesia and exsanguination and blood and livers were collected according to the following schedules: -12- Com pany Sanllfeatf. Ooaa not contain T S C S C B I H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 Group I I n m IV V VI Dosing Days 1-5 1-5 1-10 1-10 1-10 1-10 1-10 Tissue Collected Blood Blood and Liver Blood and Liver Blood and Liver Blood and Liver Blood and Liver Blood and Liver Sampling Time Test day 1 (2 hours post dosing) Test day 5 at sacrifice (2 hours post dosing) Test day 10 (2 hours post dosing) Test day 13 Test day 24 Test day 52 Test day 94 Five to 10 mL of blood was collected into EDTA tubes at sacrifice. The livers were weighed. The blood from all rats was refrigerated and the livers were frozen. The blood was appropriately packaged and shipped refrigerated to Jackson Laboratory, Deepwater, New Jersey where it was analyzed for total fluorine. The total fluorine content of the blood samples was determined using a Wickbold torch combustion method, followed by analysis with a fluoride ion selective electrode. The liquid blood was decomposed or volatilized in the presence of wet oxygen and swept through an oxyhydrogen flame in a closed quartz apparatus. The combustion products were collected in an aqueous absorbing solution and analyzed using a fluoride ion selective electrode. The analytical data (ppm F in each sample) was supplied to Haskell Laboratory personnel for evaluation of fluorine biopersistence. K. Treatment of Fluorine Data Noncompartmental analysis was conducted on blood fluorine data derived from rats dosed with H-23925 by using WinNonlin Version 3.0 software (Pharsight Corp, Mountain View, CA). WinNonlin software provided a means of computing derived pharmacokinetic parameters from data files including area under the curve (AUCINF), Cmax and terminal half-life (T1/2). The AUCINF (concentration x time) represents the area under the blood concentration curve from the time of dosing extrapolated to infinity. The maximum observed concentration was Cmax (concentration). The points included in determination of the terminal half-life were selected manually and given in units of time. Since the dosages and fluorine content for each positive control and the test material varied, all doses were normalized to 0.1 mmole/kg for comparative purposes. The accumulation index (AI, l/(l-e 'kt)) and bioaccumulation index (BI, Cmax x AI) were calculated and reported but not further used. H-24019 and H-24020 were used as positive controls. Dosing diluents were used as negative controls, but because of variability and limited sensitivity of the analytical method, the background was set at 0.2 ppm fluorine. Since 0.2 ppm was the fluoride concentration limit of detection, any values listed as less than 0.2 ppm were excluded from further treatment. The percent of fluorine and molecular weight of the test substance and positive controls were used as provided by the sponsor. The measurements resulting from analysis of total blood fluorine were used as received (ppm F) from Jackson Laboratory. Fluoride ion was converted to - 13- Com pany Sanitized. Does not contain TS C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 micromolar (/iM) equivalents of active component for further comparisons. The data and descriptions of data manipulation and presentation are provided in Appendix C. RESULTS AND DISCUSSION A. In-Life Toxicology (Tables 1-2, Figure 1, Appendices A-B) No deaths occurred during the study. One rat dosed with H-23925 exhibited diarrhea on test day 4. This clinical sign is considered not to be due to administration of the test substance because it was only observed on one day in a single rat. Rats dosed with H-24019 exhibited diarrhea, salivation, alopecia, black ocular discharge, and staining of various parts of the body during the dosing period. Rats dosed with H-24020 exhibited wet perineum and diarrhea during the dosing period. Alopecia was observed during the recovery period in rats dosed with H-24019, H-24020, and deionized water. The com oil and com oil/acetone negative control rats exhibited no clinical signs during the study. Comparison of body weights was complicated by the fact that there was a difference in age on test day 1 between the rats dosed with the test substance and those dosed with the positive or negative controls. This difference resulted in differences in mean body weights on test day 1. The rats dosed with the test substance, H-23925, were older and heavier in weight than the deionized water and com oil negative control and H-24020 positive control rats, but younger and lighter in weight than the com oil/acetone negative control and H-24019 positive control rats. Accounting for the age difference at study start and the expected rate of body weight gain, it appears that the mean body weights and mean body weight gains of the rats dosed with H-23925 are comparable to the negative controls and equal to or greater than the positive controls. B. Fluorine Data (Tables 3-4, Figures 2-3, Appendix C) 1. Factors Influencing Interpretation of Analysis The data used in the kinetic analysis were derived from a limited screen, and therefore several caveats and considerations are important. A couple of considerations of particular importance are (1) a single dose was used and kinetics may or may not be linear, (2) the kinetics apply only to blood, (3) steady-state may not have been achieved, and (4) the sample size is low and may impact calculation of the terminal half-life. A more complete list of considerations is shown in Appendix C. 2. Positive Controls The positive controls were H-24019 and H-24020. The H-24019 normalized [iM equivalents in rat blood continued to rise throughout the dosing period and may not have reached steady-state -14- Company Sanitized. Does not contain T S C A CBf H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 (Figure 2A). The Cmax for H-24019 was 989.85 116.90 ppm (Mean SD) with a terminal half-life of 40.5 days. The H-24019 AI was 59.0 and the BI was 58382.2. The H-24020 normalized fiM equivalents in rat blood peaked after 5 days of dosing and then decreased throughout the dosing period (Figure 2B). The Cmax for H-24020 was 518.12 44.89 ppm (Mean SD) with a terminal half-life of 8.3 days. The H-24020 AI was 12.5 and the BI was 6497.5. For each of the positive controls, blood was sampled at seven time points throughout the study, with only four of them occurring post-dose. The small sample size and analytical variability should be taken into account when using the derived terminal half-life for comparative purposes. The total internal exposure resulting from a normalized dose was described by AUCEMF/D and was the basis for comparison between positive controls and the test material. The AUCINF/D for the fluorine component was 566,479.1 for H-24019 and 70,789.6 for H-24020. 3. Test Substance The H-23925 normalized iM equivalents in rat blood continued to rise throughout the dosing period and did not reach steady-state (Figure 2C). The Cmax for H-23925 was 49.278 4.098 ppm (Mean SD) with a terminal half-life of 38 days. Blood was sampled at seven time points throughout the study, with only four of them occurring post-dose. The small sample size and analytical variability should be taken into account when using the derived terminal half-life for comparative purposes. The H-23925 AI was 55.4 and the BI was 2732.3. The total internal exposure resulting from a normalized dose was described by AUCINF/D and was the basis for comparison between H-23925 and positive controls. The AUCINF/D for the fluorine component of H-23925 was 14,886.1 as compared to AUCINF/D values of 566,479.1 and 70,789.6 for H-24019 and H-24020, respectively. The data, calculations and equations are shown in Appendix C. CONCLUSIONS Rats dosed for 10 consecutive days with 200 mg/kg H-23925 exhibited no mortality or test substance-related clinical signs of toxicity and had mean body weights and mean body weight gains that were comparable to the negative control rats. A steady-state for fluorine levels in whole blood was not achieved during the 10-day dosing period. Under the conditions of this study, administration of H-23925 to male rats for 10 consecutive days resulted in low absorption and retention of fluorine in the blood. Dose adjusted areas under the curve (AUCINF/D) for positive controls, H-24019 and H-24020, were approximately 38x and 5x the AUCINF/D for the test substance. -15- Com pany Sanitized. Does not contain T S C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 RECORDS AND SAMPLE STORAGE Specimens (if applicable), raw data, and the final report will be retained at Haskell Laboratory, Newark, Delaware, or at Iron Mountain Records Management, Wilmington, Delaware. - 16- Com pany Sanitized. Does not contain TSCA CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats_______________________________________________________ DuPont-2921 TABLES -17- Com pany Sanitized. Does not contain TS C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 TABLE 1 MEAN BODY WEIGHTS (g) Test Days 1 2 3 4 5 6 7 8 9 10 13 18 20 24 25 27 32 34 39 41 46 47 48 52 53 55 60 61 62 66 67 68 74 76 80 81 Negative Controls Deionized Com Oil: Water Com Oil Acetone 226.8 229.8 297.6 232.8 234.1 299.6 240.3 241.4 309.4 249.0 250.4 314.3 259.1 259.3 321.5 268.3 266.8 326.0 277.1 271.2 334.9 283.6 281.9 339.2 290.2 285.2 345.2 298.3 295.9 351.7 313.6 321.1 350.7 352.6 - - - 350.5 369.8 419.4 378.3 401.0 378.7 - - - 400.7 - 449.5 - 463.5 - - - 407.8 - 434.5 - 454.9 - 411.4 - - 469.7 511.0 - 528.0 - - 464.7 - 487.0 - 505.1 - 527.6 - -- - - 547.7 - 558.0 - - 515.4 - - 539.0 - 573.0 - - Positive Controls H-24019 291.5 291.5 298.3 304.1 308.6 312.7 317.5 317.3 318.4 318.9 329.1 - 359.7 387.9 - 393.9 - 416.9 - - '- - - 438.1 - - - - 523.4 - - - - 563.4 570.7 - H-24020 227.5 232.4 242.0 248.9 252.4 259.8 263.3 269.8 278.5 283.9 289.1 - 311.3 340.9 - - - 402.9 - 425.0 - 438.2 - 465.6 - 452.3 - 465.8 - - - 470.9 - - - 499.2 Test Substance H-23925 278.1 279.7 / 285.9 291.6 296.8 300.9 308.2 312.6 316.7 320.6 340.1 - 373.0 408.0 - - - - - - - - 457.2 480.3 - - - - 496.7 508.5 - - - 518.8 - - -18- Com pany Sanitized. Does not contain TSC A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 TABLE 1 (Continued) MEAN BODY WEIGHTS (g) Negative Controls Test Deionized Com Oil: Days_____Water_____Com Oil Acetone 83 88 589.5 - - 89 90 94 584.6 - 556.2 566.9 - 562.2 567.8 - Indicates the animal was not weighed. Positive Controls Test Substance H-24019 - - - 585.3 597.9 H-24020_____ H-23925 - 530.1 - - 527.8 538.7 - 536.5 - 538.9 - 19- Company Sanitized. Does not contain TSC A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 TABLE 2 MEAN BODY WEIGHT GAINS (g) Test Days 1-5 1-10 10-13 10-24 10-52 10-94 Negative Controls Deionized Com Water Com Oil Oil:Acetone 32.3 29.5 23.9 71.5 66.1 54.1 15.3 25.2 - 1.0 121.1 82.4 49.3 171.4 168.8 175.9 286.3 271.0 216.1 Positive Controls H-24019 17.1 27.4 10.2 69.0 119.2 279.0 H-24020 24.9 56.4 5.2 57.0 181.7 254.8 Test Substance H-23925 18.7 42.5 19.5 87.4 159.7 218.3 -20- jpompany Sanitized. Does not contain TS C A C B i H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 TABLE 3 MEAN BLOOD FLUORINE LEVELS Test Days 1 5 10 13 24 52 94 Negative Controls Deionized Com Oil: Water Com Oil Acetone (ppm) (ppm) (ppm) <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 0.3a (0.1)b <0.2 0.2a (0.1) 0.6C(0.6) 0.2e <0.2 0.2d <0.2 0.3a (0.1) <0.2 0.9C 0.3a (0.1) <0.2 Positive Controls Test Substance H-24019 (ppm) 2.1 (0.9) 48.8 (17.6) 61.7 (2-8) 64.5 (7.6) 42.2 (2.8) 26.9 (2.6) 13.2 (2.1) H-24020 (ppm) 62.6 (3.2) 71.7 (6.2) 54.2 (7.8) 26.6 (11.4) 10.5 (3.0) 0.9 (0.2) 0.2C (0.1) H-23925 (ppm) 9.2 (3.4) 13.4 (2.2) 15.9 (1.3) 6.4 (1.1) 5.0 (0.8) 2.6 (0.4) 1.6 (0.5) a Mean of 4 of the 5 values. One of the values was below the level of detection (LOD). b Standard deviation is in parentheses. c Mean of 3 of the 5 values. Two of the values were below the LOD. d One value. Four of the values were below the LOD. e Mean of 2 of the 5 values. Three of the values were below the LOD. -21 - Com pany Sanitized. Does not contain TSCA C8I H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 TABLE4 MEAN BLOOD FLUORINE CONCENTRATION NORMALIZED TO DOSE Test Days 1 5 10 13 24 52 94 Positive Controls H-24019 H-24020 fiM F Equivalents jttM F Equivalents 28.92 (13.3)a 89.28 (23.4) 747.69 (271.5) 518.12 (44.9) 945.85 (43.5) 391.01 (56.8) 989.85 (116.9) 191.45 (82.7) 645.54 (42.9) 74.35 (22.1) 411.38 (40.6) 4.64 (1.1) 195.38 (32.5) 0.24 (0.4) a Standard deviation is in parentheses. Test Substance H-23925 fiM F Equivalents 28.21 (10.6) 41.44 (6.9) 49.28 (4.1) 19.56 (3.6) 15.17 (2.6) 7.40 (1.2) 4.52 (1.4) - 22pom pany Sanitized. Does not contain TS C A CBS H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 FIGURES -23- Com pany Sanitized. Does not contain T S C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats STUDY PERSONNEL Study Director: Carol Finlay, B.A. Management: Judith C. Stadler, Ph.D., D.A.B.T. Primary Technician: Richard P. Mathena Blood Fluorine Data Analysis: Gary W. Jepson, Ph.D. Management: Matthew S. Bogdanffy, Ph.D., D.A.B.T. Toxicology Report Preparation: Wanda F. Dinbokowitz Laboratory Veterinarian: Wanda L. West, D.V.M., A.C.L.A.M. DuPont-2921 -7Com pany Sanitized. Does not contain TS C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 SUMMARY The objective of this study was to evaluate the potential for H-23925, when administered by gavage, to be absorbed and to accumulate in a mammalian system. Six groups of 5 male Crl:CD(SD)IGS BR rats each were given 200 mg/kg/day of H-23925. The test substance was administered to one group of 5 rats for 5 consecutive days and to 5 groups for 10 days. Approximately 2 hours after the first dose, blood was collected from the orbital sinus of each rat from the 5-dose group. On selected days (5, 10,13, 24, 52, 94) 5 rats per group were euthanized and the blood and livers were collected. Body weights and clinical signs were recorded on each day of dosing and then weekly, every other week, or every 3 weeks during the recovery period. Additionally, 3 negative controls, deionized water, com oil, and com oil/acetone (80:20), and 2 positive controls, H-24019 (10 mg/kg/day) and H-24020 (20 mg/kg/day), were tested as described for H-23925. No deaths occurred during the study. One rat dosed with the test substance, H-23925, exhibited diarrhea on test day 4. This clinical sign is considered not to be due to administration of the test substance because it was only observed on one day in a single rat. Rats dosed with H-24019 exhibited diarrhea, salivation, alopecia, black ocular discharge, and staining of various parts of the body during the dosing period. Rats dosed with H-24020 exhibited wet perineum and diarrhea during the dosing period. Alopecia was observed during the recovery period in rats dosed with H-24019, H-24020, and deionized water. The com oil and com oil/acetone negative control rats exhibited no clinical signs during the study. Comparison of body weights was complicated by the fact that there was a difference in age on test day 1 between the rats dosed with the test substance and those dosed with the positive or negative controls. Accounting for the age difference at study start and the expected rate of body weight gain, it appears that the mean body weights and mean body weight gains of the rats dosed with the test substance, H-23925, are comparable to the negative controls and equal to or greater than the positive controls. A steady-state for fluorine levels in whole blood was not achieved during 10 consecutive days of dosing with 200 mg/kg H-23925. An area under the curve (estimated to infinity) was calculated and normalized for fluorine content for the test substance and each positive control. The AUCINF/D for the fluorine component of the test substance, H-23925, was 14,886.1, compared to AUCINF/D values of 566,479.1 and 70,789.6 for the positive controls, H-24019 and H-24020, respectively. Under the conditions of this study, administration of H-23925 to male rats for 10 consecutive days resulted in low absorption and retention of fluorine in the blood. Dose adjusted areas under the curve (AUCINF/D) for positive controls, H-24019 and H-24020, were approximately 38x and 5x the AUCINF/D for the test substance. -8 Kompany Sanitized. Does not contain TSCA CBf H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 INTRODUCTION The objective of this study was to define the potential of H-23925 to be absorbed and to bioaccumulate in a mammalian system, as indicated by analytical determination of total fluorine in blood and liver. The test substance was compared to 2 positive controls that were materials previously shown to bioaccumulate in mammals. The daily dosage for the test substance, 200 mg/kg, was selected based on available toxicity data and the results of rangefinding studies. In the initial rangefinding study, a group of 5 male rats was dosed by oral gavage with H-23925 at a dosage of 2000 mg/kg for 5 consecutive days. A group of 5 male rats was dosed with deionized water and served as controls. The rats dosed with H-23925 experienced an overall mean body weight loss of 29 grams. In the next rangefinding study, 2 groups of 5 male rats were dosed by oral gavage with H-23925 at a dosage of 500 or 1000 mg/kg for 5 consecutive days. A group of 5 male rats was dosed with deionized water and served as controls. Overall mean body weight losses of 7 and 25 grams occurred in the rats dosed with the test substance. A group of 5 male rats was then dosed by oral gavage at a dosage of 125 mg/kg for 5 consecutive days. A group of 5 male rats was dosed with deionized water and served as controls. The rats dosed at 125 mg/kg experienced an overall mean body weight gain of 13 grams. The control group had an overall mean body weight gain of 14 grams. The dosage of 200 mg/kg was chosen for the main study and was expected to produce less than a 10% difference in mean body weight when compared to controls. All blood samples were analyzed for total fluorine content. This report contains the results of those analyses. Results from analyses of selected liver samples will be presented in a supplemental report. MATERIALS AND METHODS A. Test Substance and Positive Control The test substance, H-23925, was supplied by the sponsor as an amber liquid with some flock sediment. The positive controls, H-24019 and H-24020, were supplied by the sponsor as white solids. The test substance and positive controls appeared to be stable under the conditions of the study. No evidence of instability, such as a change in color or physical state, was observed. B. Test Species Male Crl:CD(SD)IGS BR rats were received from Charles River Laboratories, Inc., Raleigh, North Carolina. The Crl:CD(SD)IGS BR rat was selected on the basis of extensive experience with this strain and its suitability with respect to longevity, hardiness, sensitivity, and low incidence of spontaneous diseases. -9- Com pany Sanitized. Does not contain TSCA CBf H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 C. Animal Husbandry 1. Housing Environment Rats were housed singly in stainless steel, wire-mesh cages suspended above cage boards. Animal rooms were maintained on an approximate 12-hour light/dark cycle (fluorescent light) and at a temperature of 23 1C and a relative humidity of 50 10%. Occasional excursions outside the accepted ranges were minor and did not affect the study. 2. Feed and Water Tap water was provided ad libitum. All rats were fed PMI Nutrition International, Inc. Certified Rodent LabDiet 5002 chow. The feed is guaranteed by the manufacturer to meet specified nutritional requirements and to be free of specified contaminants. 3. Identification Prior to assignment to groups, each rat was temporarily identified by cage identification. After assignment to groups, an individual identification number was marked or tattooed on the tail of each rat. The information on the cage labels included the unique 6-digit Haskell animal number assigned to each rat. 4. Animal Health Monitoring Program As specified in the Haskell Laboratory animal health and environmental monitoring program, the following procedures are performed periodically to assure that contaminant levels are below those that would be expected to impact the scientific integrity of the study: Water samples are analyzed for total bacterial counts, and the presence of coliforms, lead, and other contaminants. Feed samples are analyzed for total bacterial, spore and fungal counts. Samples from freshly washed cages and cage racks are analyzed to ensure adequate sanitation by the cagewashers. Certified animal feed is used, guaranteed by the manufacturer to meet specified nutritional requirements and not to exceed stated maximum concentrations of key contaminants, including specified heavy metals, aflatoxin, chlorinated hydrocarbons, and organophosphates. The presence of these contaminants below the maximum concentration stated by the manufacturer would not be expected to impact the integrity of the study. The animal health and environmental monitoring program is administered by the attending laboratory animal veterinarian. - 10- Com pany Sanitized. Does not contain TSCA C B F H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 D. Quarantine and Pretest Upon arrival at Haskell Laboratory, the rats were removed from shipping cartons and quarantined for 6 days. The rats were weighed 3 times during the pretest period and examined daily for any clinically apparent signs of disease or injury. The rats were observed daily for mortality and signs of illness, injury, or abnormal behavior. On the bases of acceptable body weight gains and freedom from clinically apparent signs of disease or injury, the rats were released from quarantine by the laboratory animal veterinarian designee. E. Study Design Substance Negative Controls Deionized water Com oil Com oil:acetone Positive Controls H-24019 H-24020 Test Substance H-23925 Vehicle Dosage (mg/kg) Number of Animals Not applicable 0 0 0 30 30 30 Com oil: acetone Com oil 10 20 30 30 Deionized water 200 30 F. Assignment to Groups and Study Start After the quarantine period, the rats were selected on the bases of adequate body weight gain, freedom from any clinical signs of disease or injury, and a body weight within 20% of the mean. The selected rats were divided by computerized, stratified randomization into 6 groups of 5 rats, so that there were no statistically significant differences among group body weight means. After assignment to groups, each rat was housed individually. The last 3 digits of the animal number was marked or tattooed on the tail of each rat. The rats were between 7 and 9 weeks of age at the time of dosing. Dosing began on test day 1. Rats that were not assigned to the study were released for other laboratory purposes, or were sacrificed by carbon dioxide asphyxiation and discarded without pathological evaluation. G. Dosing Material Preparation and Administration 1. Test Substance H-23925 was mixed with deionized water so an accurate volume could be delivered. The amount of test substance each rat received was based on the body weight collected on each day of dosing and the dosing mixture concentration. The rats were dosed at a volume of 10 mL/kg of -11 - Com pany Sanitized. Does not contain T S C A CB f H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 body weight. The test substance was stirred on a magnetic stir plate throughout the dosing procedure to maintain homogeneity. 2. Positive Controls The solid positive control compounds were suspended as emulsions in their respective vehicles. Com oil was used as the vehicle for H-24019. It was necessary to dissolve H-24020 in acetone before suspending it in com oil. The ratio of acetone to com oil was 20:80. The amount each rat received was based on the body weight collected on each day of dosing and the suspension concentration. The dose volumes did not exceed 1 mL/100 g of body weight. The dosing suspensions were stirred on a magnetic stir plate throughout the dosing procedure to maintain homogeneity. 3. Negative Controls Deionized water was chosen as a negative control because it was the vehicle for the test substance. Com oil and com oil:acetone (80:20) were chosen as negative controls because they were the vehicles for the positive controls. Each negative control rat received 1 mL of com oil or com oihacetone. These rats were dosed in a separate room from the rats dosed with the test substance or positive controls. H. Body Weights All rats were weighed on each day of dosing. The positive and negative control rats were weighed weekly or every other week during the recovery period. The rats dosed with H-23925 were weighed weekly, every other week, or every 3 weeks during the recovery period. I. Mortality and Clinical Observations Cage-site examinations to detect moribund or dead rats and abnormal behavior and appearance among rats were conducted at least once daily throughout the study. At every weighing, each rat was individually handled and examined for abnormal behavior and appearance. J. Collection and Analysis of Blood and Livers Approximately 2 hours after the first dose, 1-2 mL of blood was collected into EDTA tubes from the orbital sinus of each rat from Group I. At all other selected time points, 5 rats/group were euthanized by carbon dioxide anesthesia and exsanguination and blood and livers were collected according to the following schedules: - 12- Com pany Sanitized. Does not contain j'a-CA H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 Group I I n m IV V VI Dosing Days 1-5 1-5 1-10 1-10 1-10 1-10 1-10 Tissue Collected Blood Blood and Liver Blood and Liver Blood and Liver Blood and Liver Blood and Liver Blood and Liver Sampling Time Test day 1 (2 hours post dosing) Test day 5 at sacrifice (2 hours post dosing) Test day 10 (2 hours post dosing) Test day 13 Test day 24 Test day 52 Test day 94 Five to 10 mL of blood was collected into EDTA tubes at sacrifice. The livers were weighed. The blood from all rats was refrigerated and the livers were frozen. The blood was appropriately packaged and shipped refrigerated to Jackson Laboratory, Deepwater, New Jersey where it was analyzed for total fluorine. The total fluorine content of the blood samples was determined using a Wickbold torch combustion method, followed by analysis with a fluoride ion selective electrode. The liquid blood was decomposed or volatilized in the presence of wet oxygen and swept through an oxyhydrogen flame in a closed quartz apparatus. The combustion products were collected in an aqueous absorbing solution and analyzed using a fluoride ion selective electrode. The analytical data (ppm F in each sample) was supplied to Haskell Laboratory personnel for evaluation of fluorine biopersistence. K. Treatment of Fluorine Data Noncompartmental analysis was conducted on blood fluorine data derived from rats dosed with H-23925 by using WinNonlin Version 3.0 software (Pharsight Corp, Mountain View, CA). WinNonlin software provided a means of computing derived pharmacokinetic parameters from data files including area under the curve (AUCINF), Cmax and terminal half-life (T1/2). The AUCINF (concentration x time) represents the area under the blood concentration curve from the time of dosing extrapolated to infinity. The maximum observed concentration was Cmax (concentration). The points included in determination of the terminal half-life were selected manually and given in units of time. Since the dosages and fluorine content for each positive control and the test material varied, all doses were normalized to 0.1 mmole/kg for comparative purposes. The accumulation index (AI, 1/(1-e`kt)) and bioaccumulation index (BI, Cmax x AI) were calculated and reported but not further used. H-24019 and H-24020 were used as positive controls. Dosing diluents were used as negative controls, but because of variability and limited sensitivity of the analytical method, the background was set at 0.2 ppm fluorine. Since 0.2 ppm was the fluoride concentration limit of detection, any values listed as less than 0.2 ppm were excluded from further treatment. The percent of fluorine and molecular weight of the test substance and positive controls were used as provided by the sponsor. The measurements resulting from analysis of total blood fluorine were used as received (ppm F) from Jackson Laboratory. Fluoride ion was converted to -13Gompany Sanitized. Does not contain T S C A CB) H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 micromolar (fiM) equivalents of active component for further comparisons. The data and descriptions of data manipulation and presentation are provided in Appendix C. RESULTS AND DISCUSSION A. In-Life Toxicology (Tables 1-2, Figure 1, Appendices A-B) No deaths occurred during the study. One rat dosed with H-23925 exhibited diarrhea on test day 4. This clinical sign is considered not to be due to administration of the test substance because it was only observed on one day in a single rat. Rats dosed with H-24019 exhibited diarrhea, salivation, alopecia, black ocular discharge, and staining of various parts of the body during the dosing period. Rats dosed with H-24020 exhibited wet perineum and diarrhea during the dosing period. Alopecia was observed during the recovery period in rats dosed with H-24019, H-24020, and deionized water. The com oil and com oil/acetone negative control rats exhibited no clinical signs during the study. Comparison of body weights was complicated by the fact that there was a difference in age on test day 1 between the rats dosed with the test substance and those dosed with the positive or negative controls. This difference resulted in differences in mean body weights on test day 1. The rats dosed with the test substance, H-23925, were older and heavier in weight than the deionized water and com oil negative control and H-24020 positive control rats, but younger and lighter in weight than the com oil/acetone negative control and H-24019 positive control rats. Accounting for the age difference at study start and the expected rate of body weight gain, it appears that the mean body weights and mean body weight gains of the rats dosed with H-23925 are comparable to the negative controls and equal to or greater than the positive controls. B. Fluorine Data (Tables 3-4, Figures 2-3, Appendix C) 1. Factors Influencing Interpretation of Analysis The data used in the kinetic analysis were derived from a limited screen, and therefore several caveats and considerations are important. A couple of considerations of particular importance are (1) a single dose was used and kinetics may or may not be linear, (2) the kinetics apply only to blood, (3) steady-state may not have been achieved, and (4) the sample size is low and may impact calculation of the terminal half-life. A more complete list of considerations is shown in Appendix C. 2. Positive Controls The positive controls were H-24019 and H-24020. The H-24019 normalized fiM equivalents in rat blood continued to rise throughout the dosing period and may not have reached steady-state - 14Company Sanitized. Does not contain T S C A C B l H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 (Figure 2A). The Cmax for H-24019 was 989.85 116.90 ppm (Mean SD) with a terminal half-life of 40.5 days. The H-24019 AI was 59.0 and the BI was 58382.2. The H-24020 normalized fiM equivalents in rat blood peaked after 5 days of dosing and then decreased throughout the dosing period (Figure 2B). The Cmax for H-24020 was 518.12 44.89 ppm (Mean SD) with a terminal half-life of 8.3 days. The H-24020 AI was 12.5 and the BI was 6497.5. For each of the positive controls, blood was sampled at seven time points throughout the study, with only four of them occurring post-dose. The small sample size and analytical variability should be taken into account when using the derived terminal half-life for comparative purposes. The total internal exposure resulting from a normalized dose was described by AUCINF/D and was the basis for comparison between positive controls and the test material. The AUCINF/D for the fluorine component was 566,479.1 for H-24019 and 70,789.6 for H-24020. 3. Test Substance The H-23925 normalized /zM equivalents in rat blood continued to rise throughout the dosing period and did not reach steady-state (Figure 2C). The Cmax for H-23925 was 49.278 4.098 ppm (Mean SD) with a terminal half-life of 38 days. Blood was sampled at seven time points throughout the study, with only four of them occurring post-dose. The small sample size and analytical variability should be taken into account when using the derived terminal half-life for comparative purposes. The H-23925 AI was 55.4 and the BI was 2732.3. The total internal exposure resulting from a normalized dose was described by AUCINF/D and was the basis for comparison between H-23925 and positive controls. The AUCINF/D for the fluorine component of H-23925 was 14,886.1 as compared to AUCINF/D values of 566,479.1 and 70,789.6 for H-24019 and H-24020, respectively. The data, calculations and equations are shown in Appendix C. CONCLUSIONS Rats dosed for 10 consecutive days with 200 mg/kg H-23925 exhibited no mortality or test substance-related clinical signs of toxicity and had mean body weights and mean body weight gains that were comparable to the negative control rats. A steady-state for fluorine levels in whole blood was not achieved during the 10-day dosing period. Under the conditions of this study, administration of H-23925 to male rats for 10 consecutive days resulted in low absorption and retention of fluorine in the blood. Dose adjusted areas under the curve (AUCINF/D) for positive controls, H-24019 and H-24020, were approximately 38x and 5x the AUCINF/D for the test substance. - 15- jCompany Sanitized. Does not contain TS C A CBF H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 RECORDS AND SAMPLE STORAGE Specimens (if applicable), raw data, and the final report will be retained at Haskell Laboratory, Newark, Delaware, or at Iron Mountain Records Management, Wilmington, Delaware. - 16- Company Sanitized. Does not contain TS C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 TABLES - 17Company Sanitized. Does not contain TS C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 TABLE 1 MEAN BODY WEIGHTS (g) Test Days 1 2 3 4 5 6 7 8 9 10 13 18 20 24 25 27 32 34 39 41 46 47 48 52 53 55 60 61 62 66 67 68 74 76 80 81 Negative Controls Positive Controls Test Substance Deionized Com Oil: Water Com Oil Acetone H-24019 H-24020 H-23925 226.8 229.8 297.6 291.5 227.5 278.1 232.8 234.1 299.6 291.5 232.4 279.7 240.3 241.4 309.4 298.3 242.0 285.9 249.0 250.4 314.3 304.1 248.9 291.6 259.1 259.3 321.5 308.6 252.4 296.8 268.3 266.8 326.0 312.7 259.8 300.9 277.1 271.2 334.9 317.5 263.3 308.2 283.6 281.9 339.2 317.3 269.8 312.6 290.2 285.2 345.2 318.4 278.5 316.7 298.3 295.9 351.7 318.9 283.9 320.6 313.6 321.1 350.7 329.1 289.1 340.1 352.6 - - - - - - 350.5 369.8 359.7 311.3 373.0 419.4 378.3 401.0 387.9 340.9 408.0 378.7 - - - - - - - - 393.9 - - 400.7 - - -- - - - 407.8 411.4 416.9 402.9 - 449.5 - - - - - - 434.5 - - 425.0 - 463.5 - '- - - - - 454.9 - - 438.2 - - - - - - 457.2 469.7 464.7 527.6 438.1 465.6 480.3 511.0 - - - - - - 487.0 - - 452.3 - 528.0 - - - - - '- 505.1 - - 465.8 - - - - , 523.4 - 496.7 - - - - - 508.5 547.7 - - - - - - ' 515.4 - - 470.9 ` - 558.0 - - - - - - - 539.0 563.4 - 518.8 - - - 570.7 - - 573.0 - - - 499.2 - - 18Company Sanitized. Does not contain TS C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 TABLE 1 (Continued) MEAN BODY WEIGHTS (g) Test Days 83 88 89 90 94 Negative Controls Deionized Com Oil: Water Com Oil Acetone - 589.5 - - - 584.6 - 556.2 566.9 - 562.2 567.8 - Indicates the animal was not weighed. Positive Controls Test Substance H-24019 - - - 585.3 597.9 H-24020 - - - 527.8 538.7 H-23925 530.1 - 536.5 - 538.9 - 19- Company Sanitized. Dees not contain T S C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 TABLE 2 MEAN BODY WEIGHT GAINS (g) Test Days 1-5 1-10 10-13 10-24 10-52 10-94 Negative Controls Deionized Com Water Com Oil Oil:Acetone 32.3 29.5 23.9 71.5 66.1 54.1 15.3 25.2 - 1.0 121.1 82.4 49.3 171.4 168.8 175.9 286.3 271.0 216.1 Positive Controls H-24019 17.1 27.4 10.2 69.0 119.2 279.0 H-24020 24.9 56.4 5.2 57.0 181.7 254.8 Test Substance H-23925 18.7 42.5 19.5 87.4 159.7 218.3 -20Company Sanitized. Does not contain T S C A C B l H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 TABLE 3 MEAN BLOOD FLUORINE LEVELS Test Days 1 5 10 13 24 52 94 Negative Controls Deionized Com Oil: Water Com Oil Acetone (ppm) (ppm) (ppm) <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 0.3a (0.1)b <0.2 0.2a (0.1) 0.6C(0.6) 0.2e <0.2 0.2d <0.2 0.3a (0.1) <0.2 o VnO 0.3a (0.1) <0.2 Positive Controls Test Substance H-24019 (ppm) 2.1 (0.9) 48.8 (17.6) 61.7 (2.8) 64.5 (7.6) 42.2 (2.8) 26.9 (2.6) 13.2 (2.1) H-24020 (ppm) 62.6 (3.2) 71.7 (6.2) 54.2 (7.8) 26.6 (11.4) 10.5 (3.0) 0.9 (0.2) 0.2C (0.1) H-23925 (ppm) 9.2 (3.4) 13.4 (2.2) 15.9 (1.3) 6.4 (1.1) 5.0 (0.8) 2.6 (0.4) 1.6 (0.5) a Mean of 4 of the 5 values. One of the values was below the level of detection (LOD). b Standard deviation is in parentheses. c Mean of 3 of the 5 values. Two of the values were below the LOD. d One value. Four of the values were below the LOD. e Mean of 2 of the 5 values. Three of the values were below the LOD. -21 - Company Sanitized. Does noi coniala TSCACBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 TABLE4 MEAN BLOOD FLUORINE CONCENTRATION NORMALIZED TO DOSE Test Days 1 5 10 13 24 52 94 Positive Controls H-24019 H-24020 M F Equivalents juM F Equivalents 28.92 (13.3)a 89.28 (23.4) 747.69 (271.5) 518.12 (44.9) 945.85 (43.5) 391.01 (56.8) 989.85 (116.9) 191.45 (82.7) 645.54 (42.9) 74.35 (22.1) 411.38 (40.6) 4.64 (1.1) 195.38 (32.5) 0.24 (0.4) a Standard deviation is in parentheses. Test Substance H-23925 M F Equivalents 28.21 (10.6) 41.44 (6.9) 49.28 (4.1) 19.56 (3.6) 15.17 (2.6) 7.40 (1-2) 4.52 (1.4) -22Company Sanitized. Does not contain T S C A C B i H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 FIGURES -23- Com pany Sanitized. Does not contain T S C A CBF Company Sanitized. Does not contain TSCA CBi H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats 400 1 350 300 - a"e 250 - '3 =oa0 200 aa 150 100 - 50 - FIGURE 1 MEAN BODY WEIGHTS (g) DuPont-2921 Negative Control (Deionized Water) Negative Control (Corn Oil) Negative Control (Corn Oil:Acetone) Positive Control H-24019 Positive Control H-24020 Test Substance H-23925 Test Days 10 12 - 24- H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 FIGURE 2 MICROMOLAR EQUIVALENTS IN RAT BLOOD A. Normalized Rat Blood H-24019 |iM Equivalents Resulting from a 10-Day O r a l G avage Micromolar (/xM) equivalents of H-24019 (positive control) in rat blood resulting from a 10-day oral gavage exposure. Values are means and error bars are standard deviation. B. N o r m a l i z e d R a t B l o o d H - 2 4 0 2 0 t M E q u i v a l e n t s R e s u l t i n g f r o m a 1 0 - D a y Oral Gavage Micromolar (/xM) equivalents of H-24020 (positive control) in rat blood resulting from a 10-day oral gavage exposure. Values are means and error bars are standard deviation. - 25- Com pany Sanitized. Does not contain t s c a OR! H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 C . N o r m a l i z e d R a t B l o o d H - 2 3 9 2 5 ft M E q u i v a l e n t s R e s u l t i n g f r o m a 1 0 - D a ; O ral G avage . Micromolar (/M) equivalents of H-23925 (test substance) in rat blood resulting from a 10-day oral gavage exposure. Values are means and error bars are standard deviation. - 26Company Sanfflzed. Does no! confata TSC CB! H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats________________________________________________________________ DuPont-2921 FIGURE 3 MICROMOLAR EQUIVALENTS IN TEST COMPOUND AND POSITIVE CONTROLS -V ; ' jH=23925 and Positive Conl|oT AU'ClNF/D In Rat Blood Resulting from r a i'G avage * _______________ m & :li -600000y:0 y - - - - m -i m m w * . vjS li' ' o SOOOO.O, m m w m i * :' m r - . , ' - ' 'a C 400000.0 'V ' c w c 0) 300000.0 (>0 '5 m 200000.0 (Q O E 3 100000.0 0.0 AUCINF/D N orm alized H-24019 566479.1 - 5 i :'*=->t ^ H.-24020 . . . t,4K*',4*^AH4j-2r^3M92S9Mhm IWI ' . 70789.6 - V V"-; * ^ .V;L Company Sanitized. Does not contain TSCA CBi -27 - H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 APPENDICES -28- Com pany Sanitized. Does not contain TSC A C B i H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 APPENDIX A Individual Body Weights - 29- Com pany Sanitized. Does not contain TS C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats______________________ ________________________________ DuPont-2921 INDIVIDUAL BODY WEIGHTS EXPLANATORY NOTES ABBREVIATIONS: SD - sacrificed by design - 30- Company Sanffized. Does not contain TS C A CBt H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats______________________________________________________________________________________DuPont-2921 DEIONIZED WATER (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP I ANIMAL NUMBER DAY 1 DAY 2 TEST DAYS DAY 3 DAY 4 DAY 5 632649 632650 632651 632652 632653 208.8 223.3 238.6 243.4 210.5 208.2 231.1 243.1 240.0 210.5 219.8 239.3 253.6 253.0 217.6 225.1 243.7 260.8 257.3 223.0 240.4 261.7 276.7 272.4 236.0 SD test day 5 SD test day 5 SD test day 5 SD test day 5 SD test day 5 Company Sanitized. Does not contain TSCA CBI -31 - H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats ANIMAL NUMBER 632654 632655 632656 632657 632658 DAY 1 210.1 234.4 236.4 251.5 220.8 DAY 2 217.0 238.1 243.5 255.0 227.5 DEIONIZED WATER (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP II TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 227.9 248.1 250.2 265.0 235.1 236.0 258.7 258.0 277.0 240.8 248.5 265.7 261.9 292.0 249.3 259.9 278.0 272.2 297.3 256.7 270.6 289.3 280.3 308.0 264.1 ANIMAL NUMBER 632654 632655 632656 632657 632658 DAY 8 282.8 295.4 286.5 317.0 274.3 DAY 9 286.6 307.1 286.1 324.3 278.2 TEST DAYS DAY 10 303.1 315.8 294.5 329.6 286.0 SD test day 10 SD test day 10 SD test day 10 SD test day 10 SD test day 10 DuPont-2921 Company Sanitized. Does not contain TSCA CBI -32- H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats___________________________ DEIONIZED WATER (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS ANIMAL NUMBER Day 1 Day 2 TEST DAYS Day 3 Day 4 GROUP III Day 5 Day 6 Day 7 632659 632660 632661 632662 632663 199.9 232.6 238.1 248.1 219.4 208.0 238.9 243.1 255.5 227.9 211.0 240.7 247.4 261.5 229.9 220.9 251.8 258.1 269.7 241.7 231.0 260.8 265.7 279.8 249.9 238.9 268.0 273.5 286.2 257.7 247.8 275.7 285.0 292.8 265.2 ANIMAL NUMBER 632659 632660 632661 632662 632663 Day 8 254.1 279.4 291.8 297.0 272.0 Day 9 261.5 286.1 302.4 302.4 276.4 TEST DAYS Day 10 Day 13 270.0 296.3 304.5 309.2 285.1 293.1 309.1 334.9 331.1 299.9 SD test day 13 SD test day 13 SD test day 13 SD test day 13 SD test day 13 DuPont-2921 Company Sanitized. Does not contain TSCA CBI -33 - 6-- ------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats______________________________________________________ DEIONIZED WATER (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP IV ANIMAL NUMBER Day 1 Day 2 TEST DAYS Day 3 Day 4 Day 5 Day 6 Day 7 632664 632665 632666 632667 632668 208.2 228.3 245.8 254.3 218.7 213.9 236.6 251.0 262.3 226.8 219.9 244.9 263.4 272.0 238.5 226.1 252.4 273.8 285.6 249.3 236.6 264.0 282.8 293.6 260.3 242.9 274.3 297.4 300.6 270.1 252.6 282.1 310.0 315.2 282.0 DuPont-2921 ANIMAL NUMBER 632664 632665 632666 632667 632668 Day 8 256.0 288.0 314.6 319.9 291.6 Day 9 262.8 297.9 326.9 330.0 301.7 TEST DAYS Day 10 Day 13 273.2 306.5 334.0 342.1 314.7 _a _a _a _a a Day 18 318.2 367.1 398.1 414.4 385.7 Day 24 349.0 408.5 441.8 460.4 437.5 SD test day 24 SD test day 24 SD test day 24 SD test day 24 SD test day 24 Company Sanitized. Does not contain TSCACW a Rats not weighed. -34- -t-i*-**' H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats______________________________________________________________________________________DuPont-2921 DEIONIZED WATER (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS ANIMAL NUMBER Day 1 Day 2 TEST DAYS Day 3 Day 4 GROUP V Day 5 Day 6 Day 7 632669 632670 632671 632672 632673 194.4 224.5 226.8 256.3 217.3 197.8 228.6 230.9 267.1 224.8 202.5 237.4 237.2 272.4 230.8 209.5 246.7 243.5 281.3 241.3 215.1 251.9 249.0 295.1 248.2 221.4 259.9 256.9 304.6 258.6 228.1 268.8 262.0 315.4 265.7 ANIMAL NUMBER 632669 632670 632671 632672 632673 Day 8 234.S 271.0 268.0 319.4 268.9 Day 9 232.6 271.0 273.6 328.4 276.4 TEST DAYS Day 10 Day 13 239.6 280.9 276.0 334.8 285.2 _a _a _a _a _a Day 18 278.1 328.3 308.4 389.8 335.6 Day 24 Day 25 _a 301.2 _a 361.5 _a 346.2 _a 441.1 _a 370.8 ANIMAL NUMBER 632669 632670 632671 632672 632673 Day 32 Day 39 TEST DAYS Day 46 Day 52 322.8 389.9 378.5 377.5 400.9 355.5 415.7 421.9 517.0 433.8 366.6 434.9 434.6 542.7 457.3 392.4 449.1 456.4 566.6 484.2 SD test day 52 SD test day 52 SD test day 52 SD test day 52 SD test day 52 a Rats not weighed. -35- Company Sanitized. Does not contain TSCA C H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats____________________________________________________________ DEIONIZED WATER (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP VI ANIMAL NUMBER Day 1 Day 2 TEST DAYS Day 3 Day 4 Day 5 Day 6 Day 7 632674 632675 632676 632677 632678 197.0 228.8 238.3 238.1 211.3 205.1 239.3 243.2 240.7 227.6 214.1 243.1 252.0 248.2 233.9 221.7 255.3 259.8 255.9 244.4 232.7 264.9 270.3 261.7 253.6 242.0 271.8 280.9 276.0 262.6 250.9 278.0 289.4 282.0 266.0 ANIMAL NUMBER 632674 632675 632676 632677 632678 Day 8 261.7 285.7 294.1 289.0 278.3 Day 9 266.0 291.6 300.3 298.0 286.3 TEST DAYS Day 10 Day 13 Day 18 Day 24 Day 25 276.7 _a 336.2 _a 380.4 296.7 _a 352.9 _a 389.6 309.8 _a 368.3 _a 411.3 302.7 _a 356.9 _a 397.5 291.4 _a 351.4 _a 387.6 ANIMAL NUMBER 632674 632675 632676 632677 632678 Day 32 Day 39 TEST DAYS Day 46 Day 52 Day 53 Day 60 Day 67 419.5 433.4 441.0 423.9 419.3 465.7 482.3 484.3 458.8 460.1 471.8 485.0 502.4 472.8 467.2 508.2 536.0 530.2 492.8 487.8 529.6 540.7 552.8 514.7 502.0 545.8 584.8 565.0 525.1 518.0 566.2 592.2 571.8 536.4 523.5 a Rats not weighed. -36- DuPont-2921 H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats ANIMAL NUMBER Day 74 Day 81 ____________________________ DEIONIZED WATER (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP VI TEST DAYS Day 88 Day 94 632674 632675 632676 632677 632678 581.9 612.8 587.0 544.2 539.3 _a 583.5 548.9 SD test 94 _a 645.4 652.9 SD test _a 605.1 603.2 SD test _a 562.0 569.4 SD test _a 551.6 548.5 SD test DuPont-2921 Company SanfUzed. Does Ioo3 a Rats not weighed. 0 H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats______________________________________________________________________________________DuPont-2921 CORN OIL (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP I ANIMAL NUMBER DAY 1 DAY 2 TEST DAYS DAY 3 DAY 4 DAY 5 627789 627801 627805 627810 627818 222.6 215.9 249.4 230.5 229.7 220.7 209.1 250.1 231.6 228.6 223.5 223.5 263.3 241.9 239.1 236.9 233.5 273.6 254.4 252.4 247.7 240.1 283.7 265.0 260:2 SD test day 5 SD test day 5 SD test day 5 SD test day 5 SD test day 5 Company SanWzed, Does nocontaFn TSCA CB - 38- m H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats ANIMAL NUMBER DAY 1 DAY 2 CORN OIL (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP II TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 627793 627797 627799 627800 627808 214.8 239.9 228.9 246.9 235.6 224.4 245.9 231.4 252.8 241.6 232.1 257.3 242.3 265.2 250.1 243.1 267.5 246.2 279.3 262.1 249.9 280.7 258.9 283.6 270.4 257.0 288.0 261.5 295.5 284.1 262.0 290.9 266.4 300.1 287.4 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 627793 627797 627799 627800 627808 270.6 3.03.9 280.2 312.0 303.6 274.9 305.1 284.3 315.4 305.7 283.5 324.2 294.7 331.3 321.8 SD test day 10 SD test day 10 SD test day 10 SD test day 10 SD test day 10 m DuPont-2921 Company Sanitized. Does not contain TSCA CBI -39- H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats___________________________________________ CORN OIL (NEGATIVE CONTROL) ANIMAL NUMBER DAY 1 DAY 2 INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP III TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 627796 627806 627807 627809 627816 239.8 227.3 221.5 234.2 235.0 249.7 234.2 225.9 240.4 238.6 253.6 239.4 237.1 252.5 250.0 252.5 242.9 244.1 260.3 258.9 267.7 258.5 254.9 272.8 265.1 277.2 270.4 257.7 277.9 274.5 289.8 275.2 260.3 282.6 278.6 ANIMAL NUMBER 627796 627806 627807 627809 627816 DAY 8 285.9 282.8 270.7 297.9 291.8 DAY 9 TEST DAYS DAY 10 DAY 13 290.1 285.8 274.7 300.2 296.4 300.0 302.8 280.7 311.9 305.7 322.7 320.3 305.2 336.2 330.2 SD test day 13 SD test day 13 SD test day 13 SD test day 13 SD test day 13 DuPont-2921 Company Sanitized. Does not contain TSCA CBl -40- # H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats_______________________________ CORN OIL (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP IV ANIMAL NUMBER DAY 1 DAY 2 TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 627791 627794 627804 627812 627817 231.1 224.4 224.7 221.9 233.5 235.4 233.0 228.8 231.5 231.3 241.2 238.1 230.6 236.3 229.0 246.8 247.8 243.0 245.7 244.8 255.9 260.0 251.7 255.5 255.4 262.6 267.4 252.9 264.9 266.4 268.4 270.1 259.5 269.5 270.0 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 627791 627794 627804 627812 627817 274.0 286.1 267.2 278.2 277.8 279.1 289.5 270.6 282.7 280.4 285.0 295.4 278.1 294.3 294.6 _a _a a _a _a 334.4 377.4 345.8 356.5 368.7 365.6 416.7 378.1 388.4 407.3 SD test day 24 SD test day 24 SD test day 24 SD test day 24 SD test day 24 DuPont-2921 Company Sanitized. Does not contain tsoa CRI a Rats not weighed. -41 - % ......................................................................................... .................................................---------------------------------------------------------------------------------------------------------------------------------------------------# H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats________________ CORN OIL (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP V ANIMAL NUMBER DAY 1 DAY 2 TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 627792 627798 627813 627814 627815 235.,8 241,.1 214..8 217 .5 230..1 240..8 253 .4 219,.2 220..5 242,.2 244 .3 257 .6 220..5 223 .7 243 .8 247 .9 266,.1 233,.2 225 .2 255 .7 252 .,5 272 .9 239..8 233 ,.8 265..0 264..4 281,.9 243 ,.2 236 .7 270 .0 268..1 286..2 246..8 240 .6 274,.1 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 DAY 34 627792 627798 627813 627814 627815 282.4 294.3 258.7 248.0 289.2 286.4 296.3 259.2 250.7 293.4 295.2 315.7 267.9 257.3 303.3 -a -a -a 360.0 380.2 323.6 299.3 368.3 389.2 403.5 342.3 319.4 396.5 426.1 443.1 367.9 343.7 434.9 ANIMAL NUMBER DAY 41 DAY 47 TEST DAYS DAY 52 627792 627798 627813 627814 627815 456.5 470.7 395.0 358.7 462.6 482.3 496.9 407.2 372.7 487.3 496.8 517.3 416.8 386.9 505.9 SD test day 52 SD test day 52 SD test day 52 SD test day 52 SD test day 52 DuPont-2921 Company Sanitized. Does not contain TSCA CBI a Rats not weighed. - 42- H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats______________________________________________________________________________________DuPont-2921 CORN OIL (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP VI ANIMAL NUMBER DAY 1 DAY 2 TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 627795 627811 627819 627820 627821 218.0 228.6 248.8 225.5 227.5 219.5 226.3 255.3 228.9 233.2 225.3 236.7 264.9 239.2 240.7 234.3 246.1 274.4 247.9 246.1 239.4 251.5 280.4 255.6 251.2 246.2 259.6 288.0 261.3 259.8 250.1 263.6 290.3 265.3 263.9 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 DAY 34 627795 627811 627819 627820 627821 261.4 273.0 304.5 281.3 272.6 265.0 276.7 308.0 282.9 275.3 270.7 285.6 324.3 292.4 281.8 -a -a 308.0 337.8 399.7 367.2 330.1 329.8 360.6 431.2 393.0 352.9 362.0 396.4 472.5 445.5 385.6 ANIMAL NUMBER 627795 627811 627819 627820 627821 DAY 41 384.2 422.0 505.9 - 478.0 411.8 DAY 47 398.0 439.3 534.9 504.1 426.1 TEST DAYS DAY 52 DAY 55' DAY 61 _a 411.1 435.7 455.4 463.0 _a 551.7 574.4 _a 529.7 547.1 _a 439.1 459.0 DAY 68 440.7 473.6 588.6 558.6 463.3 Company Sanitized. Does not contain TSCA CBI a Rats not weighed. -43 - --------- ----------------------------------- ----------------------------- H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats ANIMAL NUMBER DAY 90 DAY 94 CORN OIL (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP VI TEST DAYS 627795 627811 627819 627820 627821 474.6 503.6 638.1 608.6 509.0 485.0 511.6 653.1 618.0 521.5 SD test day 94 SD test day 94 SD test day 94 SD test day 94 SD test day 94 # DuPont-2921 Company Sanitized. Does not contain TSCA CBi - 44- # H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats______________________________________________________________________________________DuPont-2921 CORN OIL :ACETONE (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP I ANIMAL NUMBER DAY 1 DAY 2 DAY 3 TEST DAYS DAY 4 DAY 5 625361 625363 625364 625380 625383 322.6 273.7 291.1 289.4 304.7 325.0 271.4 290.9 286.2 299.7 337.6 278.4 299.9 291.5 302.7 340.3 281.7 306.0 300.1 310.7 349.7 286.7 312.0 305.5 313.1 SD test day 5 SD test day 5 SD test day 5 SD test day 5 SD test day 5 Company Sanitized. Do -45 - H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats ANIMAL NUMBER DAY 1 DAY 2 CORN OILACETONE (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP II TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 625355 625362 625367 625368 625378 280.0 290.3 301.5 312.3 309.6 282.0 294.1 307.8 318.0 306.4 293.0 303.5 315.6 326.0 327.3 297.9 308.9 320.1 336.4 328.4 306.1 313.8 327.7 343.7 333.7 311.2 315.8 333.7 347.5 336.6 315.7 323.8 345.6 360.8 346.9 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 625355 625362 625367 625368 625378 321.7 323.9 349.1 364.2 350.1 320.9 332.3 352.4 380.8 354.2 333.6 332.9 363.8 386.7 365.4 SD test day 10 SD test day 10 SD test day 10 SD test day 10 SD test day 10 DuPont-2921 H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats ANIMAL NUMBER DAY 1 DAY 2 CORN OIL:ACETONE (NEGATIVE Control) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP III TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 625357 625358 625370 625384 625385 311.9 285.7 307.9 294.2 297.6 308.8 286.3 316.7 300.0 304.6 320.3 295.5 329.5 312.0 313.0 328.4 296.4 337.9 309.3 320.4 340.5 306.0 346.9 316.3 331.9 343.3 302.7 349.8 314.1 334.0 361.1 309.2 364.1 321.4 345.4 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 625357 625358 625370 625384 625385 364.2 319.8 373.4 325.6 347.0 370.3 321.6 374.7 331.0 349.5 376.9 320.3 385.6 340.6 358.9 405.6 340.7 407.0 357.1 377.6 SD test day 13 SD test day 13 SD test day 13 SD test day 13 SD test day 13 DuPont-2921 'Company Sanitized. Does not contain TSCA CBI -47- % H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats___________________________________________________________ CORN OILACETONE (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP IV ANIMAL NUMBER DAY 1 DAY 2 TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 625354 625365 625371 625376 625381 303.0 327.7 294.5 289.7 297.8 304.1 328.7 299.0 289.9 297.5 310.5 337.9 313.4 302.2 301.7 312.2 343.6 318.3 304.9 305.6 319.3 357.7 321.8 313.2 314.4 324.7 357.2 329.6 317.0 314.4 331.2 364.3 338.5 322.8 321.0 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 625354 625365 625371 625376 625381 336.2 370.5 340.3 331.5 321.6 337.0 379.3 345.9 339.0 329.1 348.8 381.2 351.2 345.2 331.6 355.8 407.1 372.6 363.2 341.2 377.7 438.2 413.0 399.7 358.2 396.1 459.6 447.3 432.9 381.8 SD test day 24 SD test day 24 SD test day 24 SD test day 24 SD test day 24 # DuPont-2921 fcwnpany sanitized. Does nt ntain TSCACiti - 48- J2ompany Sanitized. Does not contain TSCA CBf H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats___________________________________________ CORN OILACETONE (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS ANIMAL NUMBER DAY 1 DAY 2 GROUP V TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 625356 625359 625360 625372 625374 291.7 297.9 296.8 294.8 295.9 291.2 303.3 300.7 298.8 302.2 304.5 314.0 308.5 310.6 312.1 307.0 315.0 312.7 317.4 321.7 316.9 323.5 319.1 324.0 323.4 319.8 323.5 332.2 329.0 328.3 323.9 333.9 339.5 335.6 337.2 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 DAY 27 625356 625359 625360 625372 625374 328.8 339.1 347.9 344.7 338.0 334.7 346.2 354.3 348.8 344.6 341.3 353.6 363.4 355.1 350.8 361.9 372.9 381.7 373.1 371.5 396.7 410.0 419.8 395.1 401.3 _a __a _a _a 431.3 440.9 465.9 432.1 447.2 ANIMAL NUMBER DAY 34 DAY 52 TEST DAYS 625356 625359 625360 625372 625374 466.2 467.7 484.1 454.7 466.8 533.7 530.3 555.4 506.2 512.3 SD test day 52 SD test day 52 SD test day 52 SD test day 52 SD test day 52 a Rats not weighed. - 49- DuPont-2921 Company Sanitized. Does not contain TSCA f u H-23925: Biopersistence Screening 10-Dose Oral. Gavage Study in Rats ANIMAL NUMBER DAY 1 DAY 2 CORN OIL:ACETONE (NEGATIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP VI TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 625353 625369 625373 625375 625377 305.9 281.7 294.6 289.1 293.9 307.3 279.9 301.3 291.0 294.8 316.8 289.7 312.7 298.0 302.9 325.0 286.9 317.0 307.0 312.0 331.7 292.8 325.4 309.6 318.0 330.1 295.3 . 329.0 314.2 317.4 342.5 303.8 334.6 323.5 325.0 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 DAY 27 625353 625369 625373 625375 625377 344.7 307.3 340.6 324.7 325.0 352.7 311.9 348.2 336.0 333.7 358.1 317.2 352.6 336.9 340.7 371.7 331.1 371.5 350.1 353.5 399.1 347.6 402.3 387.9 376.3 _a _a --a _a _a 427.7 374.9 444.6 432.3 405.2 ANIMAL NUMBER DAY 34 DAY 52 TEST DAYS DAY 76 DAY 90 DAY 94 625353 625369 625373 625375 625377 453.3 388.2 477.1 - 455.6 419.1 _a _a _a _a _a 544.9 483.8 628.8 567.3 470.3 562.8 505.3 661.3 589.8 492.0 565.3 514.8 673.7 588.8 496.6 SD test day 94 SD test day 94 SD test day 94 SD test day 94 SD test day 94 a Rats not weighed. - 50- # DuPont-2921 fa-- I'- it. t X U t iU H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats ANIMAL NUMBER DAY 1 DAY 2 H-24019 (POSITIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP I TEST DAYS DAY 3 DAY 4 DAY 5 625322 625323 625336 625343 625349 290.3 285.0 316.5 288.2 303.6 283.7 285.5 313.5 281.9 295.9 291.5 290.2 320.1 286.8 308.2 298.9 290.9 327.1 291.0 310.1 298.0 294.0 329.0 293.7 318.1 SD test day 5 SD test day 5 SD test day 5 SD test day 5 SD test day 5 DuPont-2921 Company Sanitized. Does not contain TSCA CBI -51 - # H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats______________________________________________________________________________________DuPont-2921 H-24019 (POSITIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS ANIMAL NUMBER DAY 1 DAY 2 GROUP II TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 625320 625330 625332 625341 625350 279.3 286.7 300.0 304.9 257.1 283.0 286.1 295.9 309.0 268.5 287.7 291.1 304.1 317.5 267.3 288.4 296.5 308.8 320.0 272.2 295.9 304.0 315.0 325.1 272.6 299.4 302.3 322.4 327.5 276.3 300.6 306.7 320.7 327.4 283.6 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 625320 625330 625332 625341 625350 308.5 314.0 324.1 332.4 279.8 306.3 312.6 321.8 320.3 282.5 312.1 310.1 318.3 325.6 284.3 SD test day 10 SD test day 10 SD test day 10 SD test day 10 SD test day 10 Company Sanitized. Does not contain TSCA CBI - 52- H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats ANIMAL NUMBER DAY 1 DAY 2 H-24019 (POSITIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP III TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 625321 625327 625342 625345 625348 307.0 311.4 273.7 291.2 265.5 307.8 306.6 275.5 291.7 258.6 311.4 312.5 282.3 297.3 268.0 319.6 317.8 285.8 303.3 275.2 322.3 318.3 290.8 306.4 280.1 328.4 319.3 294.2 310.4 285.2 335.2 327.6 326.6 316.1 290.6 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 625321 625327 625342 625345 625348 337.8 334.3 304.3 317.3 302.7 339.6 337.0 305.9 312.9 306.5 346.1 336.3 307.8 315.0 309.7 371.2 355.3 324.4 336.9 336.4 SD test day 13 SD test day 13 SD test day 13 SD test day 13 SD test day 13 DuPont-2921 Company Sanitized. Does nof contain TSCA CBI -53 - m H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats ANIMAL NUMBER DAY 1 DAY 2 H-24019 (POSITIVE CONTROL) INDIVIDUAL BODY WEIGHTS {g ) OF MALE RATS GROUP IV TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 625325 625328 625338 625340 625352 282.8 315.6 264.6 304.0 285.5 285.9 315.2 261.9 309.2 283.9 291.7 323.9 268.5 316.9 289.1 295.5 327.7 272.6 326.0 299.6 303.2 335.0 275.7 329.8 307.9 309.2 340.4 281.9 334.1 308.2 308.3 340.1 284.4 338.4 312.4 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 625325 625328 625338 625340 625352 318.6 352.0 287.4 347.0 316.9 321.9 351.7 291.3 352.2 322.3 327.4 357.5 290.2 359.2 321.0 331.6 367.4 291.1 368.1 329.6 355.8 400.2 320.4 389.3 355.7 381.3 423.9 339.9 419.0 375.3 SD test day 24 SD test day 24 SD test day 24 SD test day 24 SD test day 24 DuPont-2921 Company Sanitized. Does no! contain TSCA CBI - 54- Company SanHbed. Does not contain TSCA CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats ANIMAL NUMBER DAY 1 DAY 2 H-24019 (POSITIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP V TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 625324 625329 625333 625334 625344 303.0 318.9 292.4 274.6 262.9 298.5 316.3 291.2 277.0 262.2 305.8 326.5 297.8 286.4 269.0 312.1 335.4 304.1 290.6 273.5 320.1 338.3 307.7 292.0 274.5 322.8 346.7 312.0 ' 300.1 284.1 326.8 351.6 313.5 304.2 - ANIMAL NUMBER 625324 625329 625333 625334 625344 DAY 8 332.5 352.5 315.8 292.6 280.7 DAY 9 337.9 360.1 316.7 302.2 285.2 TEST DAYS DAY 10 DAY 13 336.1 357.0 319.3 305.8 289.3 299.6 364.3 325.8 312.0 295.8 DAY 20 336.0 396.4 349.2 338.6 309.7 DAY 24 _a _a _a _a _a DAY 27 380.3 423.3 375.2 368.8 330.4 ANIMAL NUMBER DAY 34 DAY 52 TEST DAYS 625324 625329 625333 625334 625344 397.3 442.7 384.6 384.2 348.3 447.4 498.1 427.4 426.5 391.0 SD test day 52 SD test day 52 SD test day 52 SD test day 52 SD test day 52 a Rats not weighed. -55 - DuPont-2921 m H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats____________________ H-24019 (POSITIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS ANIMAL NUMBER DAY 1 DAY 2 GROUP VI TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 DuPont-2921 625326 625335 625346 625347 625351 313.2 301.0 290.2 266.0 310.6 317.1 303.6 293.4 275.6 310.9 325.5 302.3 300.2 287.7 321.1 330.9 310.4 309.5 300.0 329.6 336.2 315.1 313.5 308.5 338.2 336.0 299.6 318.6 316.6 341.6 293.6 326.0 326.9 340.7 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 DAY 27 625326 625335 625346 625347 625351 311.5 294.2 292.9 330.5 351.1 308.9 285.3 290.8 330.1 357.8 297.5 274.0 288.4 333.0 350.5 274.2 266.3 296.9 355.7 380.0 335.4 340.1 352.5 402.1 413.7 _a __a _a _a 390.7 393.8 388.2 436.2 452.4 ANIMAL NUMBER DAY 34 DAY 52 TEST DAYS DAY 62 DAY 76 DAY 80 DAY 90 DAY 94 625326 oO 625335 625346 625347 8o 625351 3 427.5 427.0 407.4 466.4 483.3 _a _a _a _a __a 497.5 506.0 485.8 568.6 559.0 540.0 538.6 523.7 617.8 596.8 547.9 547.7 532.8 618.1 607.2 565.2 562.1 542.4 632.6 624.0 577.5 579.5 556.9 638.9 636.8 SD test day 94 SD test day 94 SD test day 94 SD test day 94 SD test day 94 o>CO on a Rats not weighed. Company Sanitized. H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats______________________________________________________________________________________DuPont-2921 H-24020 (POSITIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP I ANIMAL NUMBER DAY 1 DAY 2 TEST DAYS DAY 3 DAY 4 DAY 5 627756 627767 627771 627773 627777 227.2 227.0 219.5 246.8 225.4 226.4 231.8 214.7 244.4 221.4 233.4 237.9 226.1 252.7 232.9 238.6 245.8 233.5 263.8 239.4 237.5 248.6 239.6 262.3 236.0 SD test day 5 SD test day 5 SD test day 5 SD test day 5 SD test day 5 Company Sanitized. Does not contain TSCAC91 - 57- % H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats_____________________________________________ H-24020 (POSITIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS ANIMAL NUMBER DAY 1 DAY 2 GROUP II TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 627768 627774 627776 627782 627785 236.9 258.6 212.0 221.6 220.3 244.1 261.6 216.3 228.3 221.7 245.2 275.8 223.7 237.3 234.7 256.5 283.4 226.6 239.0 238.4 256.2 289.3 229.6 238.8 241.8 265.5 301.5 233.7 244.7 250.5 271.4 303.2 236.9 246.7 255.6 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 627768 627774 627776 627782 627785 272.3 319.8 246.1 251.0 260.7 291.9 326.3 252.3 264.0 268.5 293.5 338.2 254.4 268.2 267.9 SD test day- 10 SD test day 10 SD test day 10 SD test day 10 SD test day 10 DuPont-2921 .Company SanHIzed. Does not contain TSCA C. - 58- H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats__________ H-24020 (POSITIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS ANIMAL NUMBER DAY 1 DAY 2 GROUP III TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 627758 627763 627764 627787 627788 235.1 212.1 230.0 235.1 219.4 240.3 218.3 235.0 241.0 222.3 248.6 226.5 246.1 250.1 232.2 255.8 234.3 251.3 257.2 239.6 261.2 230.8 254.8 258.6 247.6 272.0 235.5 261.7 237.6 256.7 ' 276.1 238.0 264.7 240.3 257.9 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 627758 627763 627764 627787 627788 280.6 255.2 275.8 221.7 274.1 283.6 261.2 281.9 235.7 276.9 295.8 272.5 288 ,0 234.7 284.8 308.7 285.8 306.7 234.9 309.4 SD test day- 13 SD test day 13 SD test day 13 SD test day 13 SD test day 13 DuPont-2921 "Company SanRized. Does noi contain TSCA CRI - 59- ---------------------------------------------------------------------------- H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats_____________________________________ H-24020 (POSITIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP IV ANIMAL NUMBER DAY 1 DAY 2 TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 627759 627761 627770 627779 627786 226.6 240.7 235.6 231.5 211.6 232.9 247.4 244.3 237.9 218.2 241.4 257.1 253.6 252.6 222.5 250.9 262.5 260.1 261.4 230.4 254.2 266.7 267.7 262.3 230.6 262.1 259.2 277.3 273.8 240.6 265.4 262.6 279.8 277.5 244.1 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 627759 627761 627770 627779 627786 277.8 240.1 291.4 289.0 251.3 284.9 257.4 301.3 293.4 255.8 288.0 266.9 306.4 301.0 257.0 _a 348.0 380.1 SD test day 24 _a 335.7 359.4 SD test day 24 _a 355.8 379.8 SD test day 24 _a . 374.4 406.2 SD test day 24 _a 304.4 326.1 SD test day 24 D u P on t-2921 Sanitized Does not contain TSOA a Rats not weighed. - 60- . .................. -- - m # H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats______________________________________________________________________________________DuPont-2921 H-24020 (POSITIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g> OF MALE RATS ANIMAL NUMBER DAY 1 DAY 2 GROUP V TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 627757 627760 627765 627772 627781 221.2 226.2 228.3 245.2 219.0 225.4 232.0 235.3 256.4 226.3 236.3 244.4 247.1 266.2 236.5 241.1 251.7 251.6 277.0 242.9 247.9 260.2 256.4 276.9 247.2 252.2 254.5 261.1 285.0 251.6 254.4 258.3 264.7 291.0 256.1 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 DAY 34 627757 627760 627765 627772 627781 269.1 262.6 271.5 300.9 258.1 276.7 280.3 282.4 307.5 266.8 279.7 287.3 288.1 317.0 271.2 -a -a -a 324.3 348.6 349.8 375.5 315.1 343.0 379.9 382.7 404.0 338.8 372.3 419.4 400.9 446.9 372.0 ANIMAL NUMBER DAY 41 DAY 47 TEST DAYS DAY 52 627757 627760 627765 627772 627781 402.8 437.7 422.9 - 478.4 389.9 419.7 448.9 444.8 494.3 408.2 436.7 456.5 455.6 513.5 421.0 SD test day- 52 SD test day 52 SD test day 52 SD test day 52 SD test day 52 pnipany Sanitized. Doe. no! contain TSCA CBI a Rats not weighed. -61 - H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats ANIMAL NUMBER DAY 1 DAY 2 H-24020 (POSITIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP VI TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 627762 627769 627775 627778 627783 227.2 231.1 224.7 213.1 216.4 235.0 241.1 235.7 217.4 218.2 248.7 255.9 246.8 221.3 226.6 257.3 264.2 254.7 225.5 232.0 263.0 272.3 265.7 230.1 238.0 275.1 286.3 276.7 236.9 243.9 279.7 289.9 280.2 240.4 247.6 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 DAY 34 627762 627769 627775 627778 627783 ANIMAL NUMBER 285.9 302.0 286.6 244.8 256.6 DAY 41 299.1 309.6 296.0 250.8 259.2 DAY 47 301.5 312.5 304.5 255.1 264.3 -a TEST DAYS DAY 52 DAY 55 356.5 386.6 353.3 294.0 311.3 DAY 61 381.5 414.4 377.4 320.0 340.9 DAY 68 419.6 456.5 413.9 347.1 380.0 627762 627769 627775 627778 627783 438.7 479.7 433.2 356.8 ' 409.6 439.9 474.6 451.1 373.5 426.9 _a _a _a _a _a 453.5 512.2 460.8 386.0 449.0 473.0 511.4 477.4 393.3 473.8 471.6 531.4 478.6 398.3 474.8 a Rats not weighed. DuPont-2921 ---------------------------------------------------------------------------- % H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats____________________________ H-24020 (POSITIVE CONTROL) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS ANIMAL NUMBER DAY 81 DAY 90 TEST DAYS DAY 94 GROUP VI 627762 627769 627775 627778 627783 500.3 566.2 510.4 410.1 508.8 523.3 603.2 537.5 436.5 538.5 528.6 609.6 552.8 445.3 557.2 SD test day 94 SD test day 94 SD test day 94 SD test day 94 SD test day 94 DuPont-2921 Does not contain TSCA CBI -63 - H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats ANIMAL, NUMBER DAY 1 DAY 2 H-23925 (TEST SUBSTANCE) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP I TEST DAYS DAY 3 DAY 4 DAY 5 626399 626407 626426 626427 626428 290.2 248.9 280.4 305.4 272.8 286.0 245.1 278.1 304.6 267.3 296.0 247.4 290.2 309.5 276.4 304.2 254.6 295.6 315.6 275.4 307.9 256.1 298.6 321.7 282.9 SD test day 5 SD test day 5 SD test day 5 SD test day 5 SD test day 5 # DuPont-2921 Company Sanitized. Does no! contain TSCA C! C? - 64- " --... --....................... Q ) # H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats_____________________________________________________________ ________ _______________ DuPont-2921 H-23925 (TEST SUBSTANCE) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP II ANIMAL NUMBER DAY 1 DAY 2 TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 626396 626397 626403 626406 626421 299.7 234.7 272.1 280.1 297.8 299.5 236.0 270.5 283.2 299.0 307.7 242.4 283.2 278.9 312.3 320.2 246.5 285.2 284.3 315.8 319.0 251.2 292.0 283.1 328.3 325.8 253.6 297.6 285.3 337.1 331.6 261.1 305.0 290.2 341.0 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 626396 626397 626403 626406 626421 341.6 265.8 311.3 291.0 350.6 346.4 271.1 317.9 292.7 354.7 345.6 277.7 320.3 300.4 364.9 SD test day 10 SD test day 10 SD test day 10 SD test day 10 SD test day 10 Company Sanitized. Does no! contain TSCA !) -65 - m H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats_______________________________________ H-23925 (TEST SUBSTANCE) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS ANIMAL NUMBER DAY 1 DAY 2 GROUP III TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 626402 626404 626409 626417 626418 253.4 280.2 291.5 271.9 283.0 261.1 281.7 292.1 276.5 287.8 273.4 287.3 291.5 277.8 294.4 280.6 289.3 300.1 280.7 296.9 289.5 298.5 303.0 290.8 302.7 292.2 299.6 303.3 292.6 311.6 296.5 308.4 311.4 300.2 318.9 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 626402 626404 626409 626417 626418 307.8 315.7 311.5 301.0 319.2 318.5 314.4 316.8 307.7 320.8 319.2 317.2 319.0 316.9 326.7 342.7 335.7 337.0 333.8 347.7 SD test day 13 SD test day 13 SD test day 13 SD test day 13 SD test day 13 w DuPont-2921 Company SanFHzetf. Doos ho! confaFn TSCA CB - 66- H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats_____________________________________________________________________________________ DuPont-2921 H-23925 (TEST SUBSTANCE) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP IV ANIMAL NUMBER DAY 1 DAY 2 TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 626405 626414 626419 626423 626424 284.4 285.5 276.5 299.8 279.0 293.9 283.6 276.1 301.4 284.3 296.7 294.3 282.3 313.8 290.0 305.0 301.2 288.3 318.5 290.5 312.1 307.6 294.3 330.8 299.7 311.3 309.3 293.9 328.2 298.9 323.8 316.7 304.5 338.7 305.5 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 626405 626414 626419 626423 626424 326.2 318.6 307.3 338.6 308.4 331.2 323.7 315.3 345.2 314.9 333.5 325.9 322.3 352.1 317.2 355.5 348.0 338.9 370.8 336.0 387.6 370.4 369.5 403.5 368.1 417.7 402.5 395.6 427.7 396.6 SD test day 24 SD test day 24 SD test day 24 SD test day 24 SD test day 24 Company SanFlfee. Does no! contain TSCA CBI -67 - Company Sanitized. Does not contain TSCA cbi H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats____________________ H-23925 (TEST SUBSTANCE) INDIVIDUAL BODY WEIGHTS (g ) OF MALE RATS ANIMAL NUMBER DAY 1 DAY 2 GROUP V TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 626411 626415 626416 626422 626425 245.0 265.1 287.7 283.5 275.3 249.1 267.3 297.0 287.6 277.3 255.5 267.9 295.5 292.3 283.6 262.0 274.4 307.8 302.9 293.2 261.4 275.4 311.0 313.3 293.6 266.0 287.4 313.7 316.0 301.1 273.6 294.7 320.7 324.9 306.6 ANIMAL NUMBER DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 DAY 48 626411 626415 626416 626422 626425 277.7 292.1 327.6 331.7 312.7 276.1 293.2 330.8 337.2 314.6 279.0 297.1 335.2 342.0 324.6 292.5 310.0 359.6 361.1 345.2 325.7 347.9 399.0 395.8 374.2 _a _a _a _a _a 411.0 416.6 481.4 481.8 481.4 ANIMAL NUMBER DAY 52 TEST DAYS 626411 626415 626416 626422 626425 430.1 440.0 508.3 ' 509.7 513.6 a Rats not weighed. - 68- DuPont-2921 %# H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats ANIMAL NUMBER DAY 1 DAY 2 H-23925 (TEST SUBSTANCE) INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS GROUP VI TEST DAYS DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 DuPont-2921 626398 626401 626408 626410 626413 ANIMAL NUMBER 626398 626401 626408 626410 626413 ANIMAL NUMBER 626398 626401 626408 626410 626413 276.5 264.0 275.6 264.8 316.8 277.4 266.6 268.8 271.5 321.4 287.6 268.3 276.6 275.5 328.7 290.2 270.6 281.9 283.6 332.2 295.0 274.0 287.9 288.5 333.4 297.8 276.7 291.9 290.5 342.2 . 306.9 283.9 300.7 293.8 345.1 DAY 8 DAY 9 TEST DAYS DAY 10 DAY 13 DAY 20 DAY 24 DAY 48 312.8 2-84.4 302.4 302.8 356.2 311.8 284.9 308.0 311.9 357.8 315.7 285.3 308.6 311.3 357.0 339.1 304.6 332.4 334.0 377.2 379.6 319.3 359.6 373.8 421.0 _a _a _a _a _a 454.5 391.1 424.1 469.6 560.1 DAY 52 DAY 62 TEST DAYS DAY 66 DAY 76 DAY 83 DAY 89 DAY 94 __a 474.1 484.9 491.3 496.7 504.8 505.5 SD test day 94 _a 421.9 432.6 442.0 450.3 451.3 455.6 SD test day 94 __a 455.3 464.4 476.8 487.1 494.6 493.4 SD test day 94 _a 505.1 515.4 521.6 531.6 538.0 542.4 SD test day 94 _a 627.0 645.1 662.1 684.8 694.0 697.5 SD test day 94 Company Sanitized. Does not contain TSCA CB a Rats not weighed. - 69- H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 APPENDIX B Individual Clinical Observations - 70- Pom pany Sanitized. Does not contain T S C A CB! H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 DEIONIZED WATER (NEGATIVE CONTROL) INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS Animal Number GROUP I Observation Test Day 632649 632650 632651 632652 632653 No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected 1-5 1-5 1-5 1-5 1-5 Animal Number 632654 632655 632656 632657 632658 GROUP II Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-10 1-10 1-10 1-10 1-10 Animal Number 632659 632660 632661 632662 632663 GROUP III Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-13 ' 1-13 1-13 1-13 1-13 -71 Company Sanitized. Does not contain TS C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 DEIONIZED WATER (NEGATIVE CONTROL) INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS Animal Number GROUP IV _____Observation_________________________ Test Day 632664 632665 632666 632667 632668 No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected 1-24 1-24 1-24 1-24 1-24 Animal Number 632669 632670 632671 632672 632673 GROUP V Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-52 1-52 1-52 1-52 1-52 Animal Number 632674 632675 632676 632677 632678 No Hair No Hair No No Hair No GROUP VI O b s e r v a t i o n ____________________ Test Day malities detected Forelimb, Bilateral malities detected Forepaw, Bilateral malities detected malities detected Forepaw, Bilateral malities detected 1-88 94 1-81 88-94 1-94 1-53 60-94 1-94 - 72- Company Sanitized. Does not contain TS C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 CORN OIL (NEGATIVE CONTROL) INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS Animal Number GROUP I Observation Test Day 627789 627801 627805 627810 627818 No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected 1-5 1-5 1-5 1-5 1-5 Animal Number 627793 627797 627799 627800 627808 GROUP II Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-10 1-10 1-10 1-10 1-10 Animal Number 627796 627806 627807 627809 627816 GROUP III Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-13 1-13 1-13 1-13 1-13 . - 73- Company Sanitized. Does not contain T S C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 CORN OIL (NEGATIVE CONTROL) INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS Animal Number GROUP IV Observation _____________ Test Day 627791 627794 627804 627812 627817 No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected 1-24 1-24 1-24 1-24 1-24 Animal Number 627792 627798 627813 627814 627815 GROUP V Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected NO abnormalities detected Test Day 1-52 1-52 1-52 1-52 1-52 Animal Number 627795 627811 627819 627820 627821 GROUP VI Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-94 ' 1-94 1-94 1-94 1-94 -74Company Sanitized. Does not contain TSC H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 CORN OIL:ACETONE (NEGATIVE CONTROL) INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS Animal Number GROUP I Observation Test Day 625361 625363 625364 625380 625383 No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected 1-5 1-5 1-5 1-5 1-5 Animal Number 625355 625362 625367 625368 625378 GROUP II Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-10 1-10 1-10 1-10 1-10 Animal Number 625357 625358 625370 625384 625385 GROUP III Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-13 1-13 1-13 1-13 1-13 - 75- Company Sanitized. Does not contain T S C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 CORN OIL:ACETONE (NEGATIVE CONTROL) INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS Animal Number GROUP IV Observation_________________________ Test Day 625354 625365 625371 625376 625381 No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected 1-24 1-24 1-24 1-24 1-24 Animal Number 625356 625359 625360 625372 625374 GROUP V Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected NO abnormalities detected Test Day 1-52 1-52 1-52 1-52 1-52 Animal Number 625353 625369 625373 625375 625377 GROUP VI Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-94 1-94 1-94 1-94 1-94 I - 76- Com pany SantIFzed. Does not contain 7$C A CB H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 H-24019 (POSITIVE CONTROL) INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS Animal Number GROUP I Observation Test Day 625322 625323 625336 625343 625349 No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected 1-5 1-5 1-5 1-5 1-5 Animal Number 625320 625330 625332 625341 625350 GROUP II Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Diarrhea No abnormalities detected Test Day 1-10 1-10 1-10 1-4, 6-10 5 1-10 Animal Number 625321 625327 625342 625345 625348 GROUP III Observation No abnormalities detected Diarrhea No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-4, 6-13 5 1-13 1-13 1-13 1-13 - 77- .Company Sanitized. Does no! contain TSCA ca r H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 H-24019 (POSITIVE CONTROL) INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS Animal Number GROUP IV Observation Test Day 625325 625328 625338 625340 625352 No abnormalities detected No abnormalities detected No abnormalities detected Salivation No abnormalities detected No abnormalities detected 1-24 1-24 1-6, 8-24 7 1-24 1-24 Animal Number 625324 625329 625333 625334 625344 GROUP V Observation No abnormalities detected No abnormalities detected Salivation No abnormalities detected Salivation No abnormalities detected No abnormalities detected Test Day 1-52 1-6, 8-52 7 1-6, 8-52 7 1-52 1-52 Animal Number 625326 625335 625346 625347 625351 GROUP VI Observation No abnormalities detected Salivation Alopecia both front legs Alopecia abdomen No abnormalities detected Salivation Black ocular discharge Yellow-stained perineum Red-stained chin Brown-stained chin No abnormalities detected No abnormalities detected Salivation Test Day 1-6, 9-76, 77-94 7-8 76 7, 8, 9, 10, 13, 20, 27 1-6, 11-94 7-8 8 8 8 9-10 1-94 1-6, 8-94 7 - 78- Som pany SanHIzed. Does not contain TS C A CB? H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats H-24020 (POSITIVE CONTROL) INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS DuPont-2921 Animal Number 627756 627767 627771 627773 627777 GROUP I Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-5 1-5 1-5 1-5 1-5 Animal Number 627768 627774 627776 627782 627785 GROUP II Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-10 1-10 1-10 1-10 1-10 Animal Number 627758 627763 627764 627787 627788 GROUP III Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Wet perineum No abnormalities detected Diarrhea Test Day 1-13 1-13 1-13 1-5, 7-13 6 1-8, 10-13 9 -79- Sgm pany Sanitized. Does not contain TS C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats H-24020 (POSITIVE CONTROL) INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS DuPont-2921 Animal Number 627759 627761 627770 627779 627786 GROUP IV Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-24 1-24 1-24 1-24 1-24 Animal Number 627757 627760 627765 627772 627781 GROUP V Observation No abnormalities detected No abnormalities detected No abnormalities detected Wet perineum No abnormalities detected Wet perineum No abnormalities detected Test Day 1-52 1-52 1, 3-52 2 1, 3-52 2 1-52 Animal Number 627762 627769 627775 627778 627783 GROUP VI Observation No abnormalities detected Diarrhea No abnormalities detected No abnormalities detected Alopecia perineum No abnormalities detected Alopecia both front paws Alopecia right front leg Test Day 1-8, 10-94 9 1-94 1-94 81, 90, 94 1-23, 94 24, 34, 41, 47, 55, 61, 74, 81, 90 1 I - 80 ; CompanySanflfzed. Doesno!confatoTACif H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 H-23925 (TEST SUBSTANCE) INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS Animal Number GROUP I Observation_________________________ Test Day 626399 626407 626426 626427 626428 No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected 1-5 1-5 1-5 1-5 1-5 Animal Number 626396 626407 626426 626427 626428 GROUP II Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-10 1-10 1-10 1-10 1-10 Animal Number 626402 626404 626409 626417 626418 GROUP III Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Diarrhea Test Day 1-13 1-13 . 1-13 1-13 1-3,5-13 4 -81Company Sanitized. Does no! contain T S C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 H-23925 (TEST SUBSTANCE) INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS Animal Number GROUP IV Observation_____ __________________ Test Day 626405 626414 626419 626423 626424 No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected 1-24 1-24 1-24 1-24 1-24 Animal Number 626411 626415 626416 626422 626425 GROUP V Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-52 1-52 1-52 1-52 1-52 Animal Number 626398 626401 626408 626410 626413 GROUP VI Observation No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected No abnormalities detected Test Day 1-94 1-94 1-94 1-94 1-94 - 82Company Sanitized. Does not contain TSCA CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 APPENDIX C Individual Fluorine Levels - 83Company Sanitized. Does not contain T S C A CB! H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 Terms: Active % Active Mol W t Active Formulation Dose % F in Active Mol Wt F TERMS AND CALCULATIONS Fluorine containing compound The % of formulation that is made up of fluorine containing components The molecular weight of the fluorine containing components (g/mole) The mg of formulation given per kg of animal body weight The % fluorine in the fluorine containing components of the formulation (weight basis) The molecular weight of fluorine g/mol Compound Calculations: Dose Active (mg/kg) The mg of fluorine containing compound administered per kg of animal body weight. = (% active/100) x Formulation Dose Dose Active (mmole/kg) The mmole of fluorine containing compound administered per kg of animal body weight = dose [mg/kg] / Mol Wt Active [mg/mmol] Dose F (mg/kg) The mg Fluorine administered per kg of animal body weight = (% F in active/100) x Dose Active [mg/kg] Dose F (mmol/kg) The mmole of fluorine administered per kg of animal body weight = Dose F [mg/kg] / Mol Wt F [mg/mmol] Molar Ratio (Active/F) The moles of fluorine containing compound per mole of fluorine = Dose Active [mmol/kg] / Dose F [mmol/kg] Formulation Dose Normalization Factor The formulation dose that would be required to administer the amount of active needed to achieve the normalized dose = (Normalized dose of Active [mmol/kg] / Dose Active [mmol/kg]) x Formulation Dose -84- Com pany Sanitized. Does not contain T S C A CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 TERMS AND CALCULATIONS Individual Animal Measurement: ppm F in blood The ppm fluoride measured in blood Individual Animal Calculations: ppm F in Blood minus Bkg 0.2 ppm The ppm fluoride measured in plasma minus the background fluoride measured in control animal blood. In this case the value was established at 0.2 ppm. ppm F in Blood normalized to 0.1 mmol/kg Dose The ppm fluoride minus background that would be expected if the active dose was 0.1 mmol/kg instead of the actual active dose. This assumes linearity between administered dose and blood fluorine levels, but is needed because different doses of active were used in the study. = (0.1 [mmol/kg] / Active dose [mmol/kg]) x (ppm F in blood minus background) /xmolar equivalents of active in blood The /xmolar [/xmol/L] concentration of fluorine containing compound in plasma based on the ppm fluorine in plasma normalized to 0.1 mmol/kg active dose. This assumes that all plasma fluorine is derived from the fluorine-containing component in the formulation. Note: 1 ppm - 1 mg/L = (Normalized ppm [mg/L] fluorine in blood / Mol Wt F [mg/mmol]) x molar ratio active/F [mmol active/mmol F] x 1000 /xmol/mmol -85.Company Sanitized. Does not contain TS C A CBf H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats DuPont-2921 FACTORS INFLUENCING INTERPRETATION OF KINETIC ANALYSIS Considerations: - The data used for kinetic analysis was from a limited screen and extrapolation should be done cautiously. - Sample size is low - Analytical data used without validation - Steady-state not reached - Terminal phase may not be reached - Some compounds are mixtures of fluorinated compounds - Different active and formulation doses were used - Different vehicles were used to deliver formulations - The kinetics apply only to plasma, not to specific tissues or the whole body - Each compound may have very different potency for producing toxicity Assumptions: (May or may not bejustified in all cases) - Plasma fluorine concentrations are linear with respect to dose - Analytical method is appropriate for all types of compounds - Elimination kinetics can be determined based on total fluorine rather than on concentrations of individual components - Background plasma Fluorine is 0.2 ppm - % F data is the % Fluorine of the active (Fluorine containing component(s) in the formulation - Molecular weight is the molecular weight of the active component in the formulation - 86- Company Sanitized. Does nof contain TSCA CBt H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats Data for H- 24019 DuPont-2921 Given: Mol Wt. Active (g/mole): Formulation Dose (mg/kg): % Active (F Containing) in Formulation: 497 10 100 % F in Active: Mol Wt. F (g/mol): 65 19 Calculated Values: Dose Active (mg/kg): Dose Active (mmole/kg): Formulation Dose Normalization Factor: 10 0.020 49.7 Dose F (mmol/kg): 0.342 Molar Ratio (Active/F): 0.059 Dose F (mg/kg): 6.5 Rat Number Test ppm F Day in Sample Blood Group I 625322 625323 625336 625343 625349 1 1 1 1 1 1.0 1.3 2.6 2.6 2.9 Group I 625322 625323 625336 625343 625349 5 5 5 5 5 51.7 38.0 38.7 78.5 37.1 Group II 625320 625330 625332 625341 625350 10 10 10 10 10 65.6 61.1 60.5 63.1 58.1 ppm F in Blood Minus Bkg 0.2 ppm ppm F in Blood Normalized to 0.1 mmoles/kg Dose 0.8 3.98 1.1 5.47 2.4 11.93 2.4 11.93 2.7. 13.42 51.5 255.96 37.8 187.87 38.5 191.35 78.3 389.15 36.9 183.39 65.4 60.9 60.3 62.9 57.9 325.04 302.67 299.69 312.61 287.76 Itmolar Equivalents of Active in Blood 12.31 16.92 36.92 36.92 41.54 792.31 581.54 592.31 1204.62 567.69 1006.15 936.92 927.69 967.69 890.77 - 87- Com pany Sanitized. Does not contain t s c a CRI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats Rat Number Test ppmF Day in Sample Blood Group III 625321 625327 625342 625345 625348 13 13 13 13 13 77.2 61.5 64.6 57.0 62.4 Group IV 625325 625328 625338 625340 625352 24 24 24 24 24 40.3 46.3 43.2 39.1 41.9 Group V 625324 625329 625333 625334 625344 52 52 52 52 52 24.7 29.8 27.3 29.1 23.8 Group VI 625326 625335 625346 625347 625351 94 94 94 94 94 12.4 16.4 13.1 11.0 11.6 ppm F in Blood Minus Bkg 0.2 ppm 77.0 61.3 64.4 56.8 62.2 40.1 46.1 43.0 38.9 41.7 24.5 29.6 27.1 28.9 23.6 12.2 16.2 12.9 10.8 11.4 ppm F in Blood Normalized to 0.1 mmoles/kg Dose 382.69 304.66 320.07 282.30 309.13 199.30 229.12 213.71 193.33 207.25 121.77 147.11 134.69 143.63 117.29 60.63 80.51 64.11 53.68 56.66 DuPont-2921 /molar Equivalents of Active in Blood 1184.62 943.08 990.77 873.85 956.92 616.92 709.23 661.54 598.46 641.54 376.92 455.38 416.92 444.62 363.08 187.69 249.23 198.46 166.15 175.38 -88- Oompany Sanitized. Does not contain TSCA CBI H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats Data for H- 24020 DuPont-2921 Given: Mol Wt. Active (g/mole): Formulation Dose (mg/kg): %Active (F Containing) in Formulation: 426 20 100 %F in Active: Mol Wt. F (g/mol): 69 19 Calculated Values: Dose Active (mg/kg): Dose Active (mmole/kg): Formulation Dose Normalization Factor: 20 0.047 42.6 Dose F (mmol/kg): 0.726 Molar Ratio (Active/F): 0.065 Dose F (mg/kg): 13.8 Rat Number Test ppm F Day in Sample Blood Group I 627773 627771 627767 627756 627777 1 1 1 1 1 13.2 8.1 16.5 14.1 10.7 Group I 627773 627771 627767 627756 627777 5 5 5 5 5 75.3 66.8 64.8 80.0 71.6 Group II 627768 627774 627776 627782 627785 10 10 10 10 10 56.3 51.0 54.8 43.6 65.1 ppm F in Blood Minus Bkg 0 2 PPm____ ppm F in Blood Normalized to 0.1 mmoles/kg Dose 13.0 27.69 7.9 16.83 16.3 34.72 13.9 29.61 10.5 22.37 75.1 159.96 66.6 141.86 64.6 137.60 79.8 169.97 71.4 152.08 56.1 50.8 54.6 43.4 64.9 119.49 108.20 116.30 92.44 138.24 /molar Equivalents of Active in Blood 94.20 57.25 118.12 100.72 76.09 544.20 482.61 468.12 578.26 517.39 406.52 368.12 395.65 314.49 470.29 - 89- Com pany Sanitized. Does not contain TSCA CBl H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats_______________________________ Rat Number Test ppm F Day in Sample Blood ppm F in Blood Minus Bkg 0.2 ppm ppm F in Blood Normalized to 0.1 mmoles/kg Dose Group III 627758 627764 627787 627763 627788 13 13 13 13 13 43.5 20.7 13.2 30.8 24.9 43.3 20.5 13.0 30.6 24.7 92.23 43.67 27.69 65.18 52.61 Group IV 627759 627779 627770 627761 627786 24 24 24 24 24 9.2 14.9 11.6 9.9 6.7 9.0 14.7 11.4 9.7 6.5 19.17 31.31 24.28 20.66 13.85 Group V 627757 627781 627760 627765 627772 52 52 52 52 52 . 0.9 0.6 1.0 0.9 0.8 0.7 0.4 0.8 0.7 0.6 1.49 0.85 1.70 1.49 1.28 Group VI 627778 627783 627762 627775 627769 94 94 94 94 94 0.3 <0.2 0.2 0.2 <0.2 0.1 * 0.0 0.0 * 0.21 * 0.00 0.00 * DuPont-2921 /onolar Equivalents of Active in Blood 313.77 148.55 94.20 221.74 178.99 65.22 106.52 82.61 70.29 47.10 5.07 2.90 5.80 5.07 4.35 0.72 * 0.00 0.00 * * = Below LOD (Level of Detection) -90- Com pany Sanitized. Does no! contain TSCA C1 H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats Data for H-23925 DuPont-2921 Given: Mol Wt. Active (g/mole): Formulation Dose (mg/kg): % Active (F Containing) in Formulation: 669.5 200 29 % F in Active: Mol Wt. F (g/mol): 55 19 Calculated Values: Dose Active (mg/kg): Dose Active (mmole/kg): Formulation Dose Normalization Factor: 58 Dose F (mmol/kg): 1.679 0.087 Molar Ratio (Active/F): 0.052 230.9____ Dose F (mg/kg):_________31.9 Rat Number Test ppm F Day in Sample Blood Group I 626399 626407 626426 626427 626428 1 1 1 1 1 10.4 12.6 4.9 11.7 6.4 Group I 626399 626407 626426 626427 626428 5 5 5 5 5 14.7 12.9 10.7 16.4 12.4 G roup II 626396 626397 626403 626406 626421 10 10 10 10 10 16.7 13.9 15.3 16.7 17.0 ppm F in Blood Minus Bkg 0.2 ppm ppm F in Blood Normalized to 0.1 mmoles/kg Dose 10.2 11.77 12.4 14.31 4.7 5.43 11.5 13.27 6.2 7.16 14.5 16.74 12.7 14.66 10.5 12.12 16.2 18.70 12.2 14.08 16.5 13.7 15.1 16.5 . 16.8 19.05 15.81 17.43 19.05 19.39 pmolar Equivalents of Active in Blood 31.97 38.87 14.73 36.05 19.44 45.45 39.81 32.92 50.78 38.24 51.72 42.95 47.34 51.72 52.66 -91- Company Sanitized. Does not contain TSC A CR. H-23925: Biopersistence Screening 10-Dose Oral Gavage Study in Rats_______________________________________________________ DuPont-2921 Rat Number Test ppm F Day in Sample Blood ppm F in Blood Minus Bkg 0.2 ppm ppm F in Blood Normalized to 0.1 mmoles/kg Dose tmolar Equivalents of Active in Blood Group III 626402 626404 626409 626417 626418 13 13 13 13 13 5.2 5.9 6.1 8.2 6.8 5.0 5.7 5.9 8.0 6.6 5.77 15.67 6.58 17.87 6.81 18.50 9.23 25.08 7.62 20.69 Group IV 626405 626414 626419 626423 626424 24 24 24 24 24 5.6 5.5 5.8 4.3 4.0 5.4 5.3 5.6 4.1 3.8 6.23 16.93 6.12 16.61 6.46 17.55 4.73 12.85 4.39 11.91 Group V 626411 52 3.0 2.8 3.23 8.78 626415 52 2.7 2.5 2.89 7.84 626416 52 2.2 2.0 2.31 6.27 626422 52 2.8 2.6 3.00 8.15 626425 52 2.1 1.9. 2.19 5.96 Group VI 626398 626401 626408 626410 626413 94 94 94 94 94 1.6 1.5 2.4 1.5 1.2 1.4 1.3 2.2 1.3 1.0 1.62 4.39 1.50 4.08 2.54 6.90 1.50 4.08 1.15 3.13 - 92- Com party Sanitized. Does not contain T S C A CBt
Contact UsLoginSign Up
CUNY - The Graduate CenterColumbia University Mailman School of Public Health - Sociomedical Sciences